AVADEL PHARMACEUTICALS PLC - Quarter Report: 2017 September (Form 10-Q)

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

———————

FORM 10-Q

———————

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: September 30, 2017

———————

AVADEL PHARMACEUTICALS PLC

(Exact name of registrant as specified in its charter)

———————



Ireland	000-28508	98-1341933
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

Block 10-1, Blanchardstown Corporate Park

Ballycoolin

Dublin 15, Ireland

(Address of Principal Executive Office and Zip Code)

+353-1-485-1200

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

———————

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes þ No ¨

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.



Large accelerated filer	¨	Accelerated filer	þ
Non-accelerated	¨	(Do not check if a smaller reporting company)
		Smaller reporting company	¨
		Emerging growth company	¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ¨

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ¨ No þ

At November 2, 2017, 39,762,209 ordinary shares, nominal value $0.01 each, of the Company were outstanding.

TABLE OF CONTENTS



		Page #
Forward Looking Statements		3

PART I - FINANCIAL INFORMATION
Item 1.	Financial Statements	4
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	23
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	40
Item 4.	Controls and Procedures	40

PART II - OTHER INFORMATION
Item 1.	Legal Proceedings	41
Item 1A.	Risk Factors	41
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	42
Item 3.	Defaults Upon Senior Securities	43
Item 4.	Mine Safety Disclosures	43
Item 5.	Other Information	43
Item 6.	Exhibits	44

- 2 -

Forward-Looking Statements

This quarterly report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934 ("Exchange Act"). The words “will,” “may,” “believe,” “expect,” “anticipate,” “estimate,” “project” and similar expressions, and the negatives thereof, identify forward-looking statements, each of which speaks only as of the date the statement is made. In particular, information appearing under “Management’s Discussion and Analysis of Financial Condition and Results of Operations” includes forward-looking statements.

Although we believe that our forward-looking statements are based on reasonable assumptions within the bounds of our knowledge of our business and operations, our business is subject to significant risks and there can be no assurance that actual results of our research, development and commercialization activities and our results of operations will not differ materially from our expectations.

More information on factors that could cause actual results or events to differ materially from those anticipated is set forth in Part II, Item 1A (“Risk Factors”) of this quarterly report on Form 10-Q and is included from time to time in our other reports filed with the Securities and Exchange Commission (SEC), including our annual report on Form 10-K for the year ended December 31, 2016, in particular under the captions “Forward-Looking Statements” and “Risk Factors.”

All forward-looking statements speak only as of the date of this report and are expressly qualified in their entirety by the risk factors and other cautionary statements included or referenced in or incorporated by reference into this report. Except as is required by law, we expressly disclaim any obligation to publicly release any revisions to forward-looking statements to reflect events after the date of this report.

- 3 -

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(In thousands, except per share data)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017			2016

Revenues:
Product sales and services	$	39,147		$	31,340		$	138,009		$	104,858
License and research revenue	528			747			484			2,303
Total	39,675			32,087			138,493			107,161
Operating expenses:
Cost of products and services sold	3,790			2,844			12,253			10,657
Research and development expenses	8,095			8,143			22,093			21,135
Selling, general and administrative expenses	11,563			12,740			35,804			33,491
Intangible asset amortization	564			3,702			1,692			10,918
(Gain)/loss - changes in fair value of related party contingent consideration	(9,906		)	20,848			(30,107		)	52,989
Restructuring (income) costs	(549		)	—			3,173			—
Total operating expenses	13,557			48,277			44,908			129,190
Operating income (loss)	26,118			(16,190		)	93,585			(22,029		)
Investment income, net	1,110			490			2,689			1,080
Interest expense, net	(263		)	(264		)	(789		)	(702		)
Other income (expense) - changes in fair value of related party payable	768			(1,828		)	2,988			(6,135		)
Foreign exchange gain (loss)	(133		)	1,249			(127		)	(12		)
Income (loss) before income taxes	27,600			(16,543		)	98,346			(27,798		)
Income tax provision	5,921			3,451			21,830			18,212
Net income (loss)	$	21,679		$	(19,994	)	$	76,516		$	(46,010	)

Net income (loss) per share - basic	$	0.54		$	(0.48	)	$	1.87		$	(1.12	)
Net income (loss) per share - diluted	0.52			(0.48		)	1.81			(1.12		)

Weighted average number of shares outstanding - basic	40,061			41,241			40,839			41,241
Weighted average number of shares outstanding - diluted	41,339			41,241			42,194			41,241

See accompanying notes to condensed consolidated financial statements.

- 4 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)

(In thousands)



	Three Months Ended September 30,						Nine Months Ended September 30,
	2017			2016			2017		2016

Net income (loss)	$	21,679		$	(19,994	)	$	76,516	$	(46,010	)
Other comprehensive income (loss), net of tax:
Foreign currency translation gain (loss)	(229		)	1,567			18		3,927
Net other comprehensive income (loss), net of $92, $152, $0 and ($49) tax, respectively	(512		)	(2,405		)	126		(958		)
Total other comprehensive income (loss), net of tax	(741		)	(838		)	144		2,969
Total comprehensive income (loss)	$	20,938		$	(20,832	)	$	76,660	$	(43,041	)

See accompanying notes to condensed consolidated financial statements.

- 5 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)



	September 30, 2017			December 31, 2016

ASSETS
Current assets:
Cash and cash equivalents	$	37,449		$	39,215
Marketable securities	78,161			114,980
Accounts receivable	24,080			17,839
Inventories, net	5,870			3,258
Prepaid expenses and other current assets	3,373			5,894
Total current assets	148,933			181,186
Property and equipment, net	3,180			3,320
Goodwill	18,491			18,491
Intangible assets, net	94,256			22,837
Research and development tax credit receivable	3,547			1,775
Income tax deferred charge	—			10,342
Other	9,020			7,531
Total assets	$	277,427		$	245,482

LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt	$	301		$	268
Current portion of long-term related party payable	30,986			34,177
Accounts payable	8,564			7,105
Deferred revenue	1,927			2,223
Accrued expenses	47,997			17,222
Income taxes	7,026			1,200
Other	507			226
Total current liabilities	97,308			62,421
Long-term debt, less current portion	614			547
Long-term related party payable, less current portion	76,131			135,170
Other	6,911			5,275
Total liabilities	180,964			203,413

Shareholders' equity:
Preferred shares, $0.01 nominal value; 50,000 shares authorized; none issued or outstanding at September 30, 2017 and December 31, 2016, respectively	—			—
Ordinary shares, nominal value of $0.01; 500,000 shares authorized; 41,435 and 41,371 issued and outstanding at September 30, 2017 and December 31, 2016, respectively	414			414
Treasury shares, at cost, 1,673 and 0 shares held at September 30, 2017 and December 31, 2016, respectively	(17,506		)	—
Additional paid-in capital	391,416			385,020
Accumulated deficit	(254,440		)	(319,800		)
Accumulated other comprehensive loss	(23,421		)	(23,565		)
Total shareholders' equity	96,463			42,069
Total liabilities and shareholders' equity	$	277,427		$	245,482

See accompanying notes to condensed consolidated financial statements.

- 6 -

AVADEL PHARMACEUTICALS PLC

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)



	Nine Months Ended September 30,
	2017			2016

Cash flows from operating activities:
Net income (loss)	$	76,516		$	(46,010	)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	2,664			11,555
Loss on disposal of property and equipment	—			110
Loss (gain) on sale of marketable securities	(550		)	666
Foreign exchange loss	127			12
Grants recognized in research and development expenses	—			(70		)
Remeasurement of related party acquisition-related contingent consideration	(30,107		)	52,989
Remeasurement of related party financing-related contingent consideration	(2,988		)	6,135
Change in deferred tax and income tax deferred charge	322			(5,680		)
Stock-based compensation expense	6,019			10,541
Increase (decrease) in cash from:
Accounts receivable	(6,240		)	(7,594		)
Inventories	(2,612		)	2,080
Prepaid expenses and other current assets	1,924			671
Research and development tax credit receivable	(1,576		)	(1,794		)
Accounts payable & other current liabilities	804			1,291
Deferred revenue	(283		)	(2,198		)
Accrued expenses	9,324			2,700
Accrued income taxes	5,826			—
Earn-out payments for related party contingent consideration in excess of acquisition-date fair value	(24,729		)	(14,486		)
Royalty payments for related party payable in excess of original fair value	(3,446		)	(1,790		)
Other long-term assets and liabilities	(517		)	2,032
Net cash provided by operating activities	30,478			11,160

Cash flows from investing activities:
Purchases of property and equipment	(533		)	(1,000		)
Acquisitions of businesses	—			628
Purchase of intangible assets	(52,139		)	—
Proceeds from sales of marketable securities	153,398			46,483
Purchases of marketable securities	(115,893		)	(96,199		)
Net cash used in investing activities	(15,167		)	(50,088		)

Cash flows from financing activities:
Earn-out payments for related party contingent consideration	(961		)	(6,834		)
Royalty payments for related party payable	—			(1,117		)
Reimbursement of loans	—			(61		)
Cash proceeds from issuance of ordinary shares and warrants	376			—
Share repurchases	(16,707		)	—
Net cash used in financing activities	(17,292		)	(8,012		)

Effect of foreign currency exchange rate changes on cash and cash equivalents	215			656

Net decrease in cash and cash equivalents	(1,766		)	(46,284		)
Cash and cash equivalents at January 1,	39,215			65,064
Cash and cash equivalents at September 30,	$	37,449		$	18,780

See accompanying notes to condensed consolidated financial statements.

- 7 -

AVADEL PHARMACEUTICALS PLC

NOTES TO THE UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(In thousands, except per share data)

NOTE 1 : Summary of Significant Accounting Policies

Nature of Operations. Avadel Pharmaceuticals plc (“Avadel,” the “Company,” “we,” “our,” or “us”) is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies:

•

the development of differentiated, patent protected products through application of the Company’s proprietary patented drug delivery platforms, Micropump® and LiquiTime®, that target high-value solid, liquid oral and alternative dosage forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn’t depend on efficacy, safety, and toxicity data created by the sponsor. In addition to Micropump® and LiquiTime®, the Company has two other proprietary drug delivery platforms, Medusa™ (hydrogel depot technology for use with large molecules and peptides) and Trigger Lock™ (controlled release of opioid analgesics with potential abuse deterrent properties).

•

the identification of Unapproved Marketed Drugs (“UMDs”), which are currently sold in the U.S., but unapproved by the FDA, and the pursuit of approval for these products via a 505(b)(2) New Drug Application (NDA). To date, the Company has received three drug approvals through this “unapproved-to-approved” strategy, including: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). As a potential source of near-term revenue growth, Avadel is working on the development of a fourth product for potential NDA submission and seeks to identify additional product candidates for development with this strategy.

•

the acquisition of commercial and or late-stage products or businesses. On September 1, 2017, the Company entered into an Exclusive License and Assignment Agreement ("ELAA") with Serenity Pharmaceuticals, LLC. The ELAA grants the Company the sole right to commercialize and further develop Noctiva™ in the United States. Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of nocturia due to nocturnal polyuria. Additionally, the Company markets three branded pediatric-focused pharmaceutical products in the primary care space, and a 510(k) approved device all of which were purchased through the acquisition of FSC Laboratories and FSC Pediatrics ("FSC") on February 5, 2016. We will consider further acquisitions and the Company continues to look for assets that could fit strategically into our current or potential future commercial sales force.

The Company was incorporated in Ireland on December 1, 2015 as a private limited company, and re-registered as an Irish public limited company on November 21, 2016. Our headquarters is in Dublin, Ireland and we have operations in St. Louis, Missouri, United States, and Lyon, France.

The Company is the successor to Flamel Technologies S.A., a French société anonyme (“Flamel”), as the result of the merger of Flamel with and into the Company which was completed at 11:59:59 p.m., Central Europe Time, on December 31, 2016 (the “Merger”) pursuant to the agreement between Flamel and Avadel entitled Common Draft Terms of Cross-Border Merger dated as of June 29, 2016 (the “Merger Agreement”). Immediately prior to the Merger, the Company was a wholly owned subsidiary of Flamel. As a result of the Merger Agreement:


•	Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel.


•	our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each


◦	all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital

◦

our Board of Directors is authorized to issue preferred shares on a non-pre-emptive basis, for a maximum period of five years, at which point it may be renewed by shareholders. The Board of Directors has discretion to dictate terms attached to the preferred shares, including voting, dividend, conversion rights, and priority relative to other classes of shares with respect to dividends and upon a liquidation.

- 8 -


•	all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company.

Thus, the Merger changed the jurisdiction of our incorporation from France to Ireland, and an ordinary share of the Company held (either directly or represented by an ADS) immediately after the Merger continued to represent the same proportional interest in our equity owned by the holder of a share of Flamel immediately prior to the Merger.

References in these condensed consolidated financial statements and the notes thereto to “Avadel,” the “Company,” “we,” "our," “us,” and similar terms shall be deemed to be references to Flamel prior to the completion of the Merger, unless the context otherwise requires.

Prior to completion of the Merger, the Flamel ADSs were listed on the Nasdaq Global Market (“Nasdaq”) under the trading symbol “FLML” and immediately after the Merger the Company’s ADSs were listed for and began trading on Nasdaq on January 3, 2017 under the trading symbol “AVDL.”

Further details about the reincorporation, the Merger and the Merger Agreement are contained in our definitive proxy statement filed with the Securities and Exchange Commission on May 1, 2017, and within the 2016 Annual Report on Form 10-K.

Under Irish law, the Company can only pay dividends and repurchase shares out of distributable reserves, as discussed further in the Company's proxy statement filed with the SEC as of July 5, 2016. Upon completion of the Merger, the Company did not have any distributable reserves. On February 15, 2017, the Company filed a petition with the High Court of Ireland seeking the court's confirmation of a reduction of the Company's share premium so that it can be treated as distributable reserves for the purposes of Irish law. On March 6, 2017, the High Court issued its order approving the reduction of the Company's share premium by $317,254 which can be treated as distributable reserves.

Basis of Presentation. The Condensed Consolidated Balance Sheet as of December 31, 2016, which is primarily derived from the prior year 2016 audited consolidated financial statements, and the interim condensed consolidated financial statements presented herein, have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP), the requirements of Form 10-Q and Article 10 of Regulation S-X and, consequently, do not include all information or footnotes required by U.S. GAAP for complete financial statements or all the disclosures normally made in an annual report on Form 10-K. Accordingly, the condensed consolidated financial statements included herein should be read in conjunction with the audited consolidated financial statements and footnotes included in the Company’s 2016 Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 28, 2017.

The condensed consolidated financial statements include the accounts of the Company and subsidiaries, and reflect all adjustments (consisting only of normal recurring adjustments) that are, in the opinion of management, necessary for a fair presentation of the Company’s financial position, results of operations and cash flows for the dates and periods presented. All material intercompany accounts and transactions have been eliminated. Results for interim periods are not necessarily indicative of the results to be expected during the remainder of the current year or for any future period.

Foreign Currency Translation. The reporting currency of the Company and our wholly-owned subsidiaries is the U.S. dollar. Subsidiaries that do not use the U.S. dollar as their functional currency translate:


•	profit and loss accounts at the weighted average exchange rates during the reporting period,


•	assets and liabilities at period end exchange rates, and


•	shareholders' equity accounts at historical rates.

Resulting translation gains and losses are included as a separate component of shareholders' equity in Accumulated Other Comprehensive Loss. Assets and liabilities, excluding available-for-sale marketable securities, denominated in a currency other than the subsidiary's functional currency are translated to the subsidiary's functional currency at period end exchange rates with resulting gains and losses recognized in the condensed consolidated statements of income (loss).

Revenue. Revenue includes sales of pharmaceutical products, amortization of licensing fees, and, if any, milestone payments for R&D achievements.

Product Sales and Services

Revenue is generally realized or realizable and earned when persuasive evidence of an arrangement exists, delivery has occurred or services have been rendered, the seller’s price to the buyer is fixed or determinable, and collectability is reasonably assured. The Company records revenue from product sales when title and risk of ownership have been transferred to the customer, which

- 9 -

is typically upon delivery to the customer and when the selling price is determinable. As is customary in the pharmaceutical industry, the Company’s gross product sales are subject to a variety of deductions in arriving at reported net product sales. These adjustments include estimates for product returns, chargebacks, payment discounts, rebates, and other sales allowances and are estimated based on analysis of historical data for the product or comparable products, as well as future expectations for such products.

For generic products and branded products sold in mature markets where the ultimate net selling price to customer is estimable, the Company recognizes revenues upon delivery to the wholesaler. For new product launches the Company recognizes revenue once sufficient data is available to determine product acceptance in the marketplace such that product returns may be estimated based on historical data and there is evidence of reorders and consideration is made of wholesaler inventory levels. As part of the third quarter 2016 launch of Akovaz, the Company determined that sufficient data was available to determine the ultimate net selling price to the customer and therefore recognized revenue upon delivery to our wholesaler customers.

Prior to the second quarter 2016, the Company did not have sufficient historical data to estimate certain revenue deductions. As such, it could not accurately estimate the ultimate net selling price of our Éclat portfolio of products and as a result delayed revenue recognition until the wholesaler sold the product through to end customers.

During the second quarter of 2016, the Company determined that it had sufficient evidence, history, data and internal controls to estimate the ultimate selling price of our products upon delivery to our customers, the wholesalers. Accordingly, we discontinued the sell through revenue approach and now recognize revenue once the product is shipped from our warehouse.

License and Research Revenue

The Company’s license and research revenues consist of fees and milestone payments. Non-refundable fees where we have continuing performance obligations are deferred and are recognized ratably over our projected performance period. We recognize milestone payments, which are typically related to regulatory, commercial or other achievements by us or our licensees and distributors, as revenues when the milestone is accomplished and collection is reasonably assured.

NOTE 2 : Newly Issued Accounting Pronouncements

In March 2017, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2017-07, "Improving the Presentation of Net Periodic Pension Cost and Net Periodic Postretirement Benefit Costs." The standard requires the service component of pension and other postretirement benefit expense to be presented in the same statement of income lines as other employee compensation costs, however, the other components will be presented outside of operating income. In addition, only the service cost component will be eligible for capitalization in assets. The standard is effective starting in 2018, with early adoption permitted. Retrospective application is required for the guidance on the statement of income presentation. Prospective application is required for the guidance on the cost capitalization in assets. The Company does not believe this standard will materially impact our consolidated financial statements.

In January 2017, the FASB issued ASU 2017-04, "Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment." This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance is effective for the Company in the first quarter of fiscal 2020. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company will assess the timing of adoption and impact of this guidance to future impairment considerations.

In January, 2017, the FASB issued ASU 2017-01, "Business Combinations (Topic 805): Clarifying the Definition of a Business." This update provides a screen to determine whether or not a set of assets is a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of similar identifiable assets, the set of assets is not a business. If the screen is not met, the amendments in this update (1) require that to be considered a business, a set of assets must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output and (2) remove the evaluation of whether a market participant could replace missing elements. This guidance is effective for the Company in the first quarter of fiscal 2018. Early adoption is permitted for transactions not previously reported in the Company's consolidated financial statements. In September, 2017 the Company entered into an ELAA to acquire from Serenity Pharmaceuticals, LLC intellectual property rights to further develop and commercialize Noctiva in the United States. The Company elected to early adopt ASU 2017-01 and determined the intangible assets acquired as part of the ELAA should be accounted for as an acquisition of a single group of assets and not as a business combination.

In October 2016, the FASB issued ASU 2016-16, "Income Taxes (Topic 740), Intra-Entity Transfers of Assets Other Than Inventory," which requires companies to recognize the income tax consequences of an intra-entity transfer of an asset other than

- 10 -

inventory when the transfer occurs. ASU 2016-16 is effective for annual reporting periods, and interim periods therein, beginning after December 15, 2017. The Company elected to early-adopt ASU 2016-16 on a modified-retrospective basis as of January 1, 2017. Adoption of ASU 2016-16 eliminated the $11,156 income tax deferred charge recorded within the consolidated balance sheet as of December 31, 2016 and such elimination is reflected as an adjustment to accumulated deficit as of January 1, 2017.

In August 2016, the FASB issued ASU 2016-15, "Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments." ASU 2016-15 identifies how certain cash receipts and cash payments are presented and classified in the Statement of Cash Flows under Topic 230. ASU 2016-15 is effective for the Company for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. ASU 2016-15 should be applied retrospectively and early adoption is permitted, including adoption in an interim period. The Company does not believe this standard will materially impact our consolidated financial statements.

In May 2014, the FASB issued ASU 2014-09 “Revenue from Contracts with Customers” which supersedes the most current revenue recognition requirements. This ASU requires entities to recognize revenue in a way that depicts the transfer of goods or services to customers in an amount that reflects the consideration which the entity expects to be entitled to in exchange for those goods or services. Through May 2016, the FASB issued ASU 2016-08 “Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” ASU 2016-10 “Identifying Performance Obligations and Licensing,” and ASU 2016-12, “Narrow-Scope Improvements and Practical Expedients,” which provide supplemental adoption guidance and clarification to ASU 2014-09, respectively. These ASUs will be effective for annual and interim periods beginning after December 15, 2017 with early adoption for annual and interim periods beginning after December 15, 2016 permitted and should be applied retrospectively to each prior reporting period presented or as a modified retrospective adjustment as of the date of adoption.

The Company is currently evaluating this pronouncement to determine the impact of adoption on our consolidated financial statements, including which transition approach will be applied. The Company has decided not to early adopt the new pronouncement. The Company has assembled an implementation team consisting of a project manager as well as a cross functional project team responsible for assessing the impact the new revenue pronouncement will have on its consolidated financial statements and related disclosures. The implementation team is in the assessment phase, which consists of in depth analysis around the Company’s contracts and will result in a comparison of historical accounting policies and practices to the requirements of the new revenue pronouncement. The implementation team will then identify any potential changes to business processes, systems and controls necessary to support recognition and disclosure under the new revenue pronouncement.

In February 2016, the FASB issued ASU 2016-02, “Leases” which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 “Leases.” This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. This update will be applied using a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the effect of this update on our consolidated financial statements.

In January 2016, the FASB issued ASU 2016-01, "Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities." The amendments in this update address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2017, and requires a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption. Early adoption is not permitted. The new guidance will require the change in fair value of equity investments with readily determinable fair values to be recognized through the statement of income. We are currently evaluating the full impact of the standard; however, upon adoption, the change in the fair value of our available-for-sale equity investments will be recognized in our consolidated statement of income (loss) rather than as a component of our consolidated statement of comprehensive income (loss).

NOTE 3 : Fair Value Measurement

The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement:

ASC 820, Fair Value Measurements and Disclosures defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, we may generally use one or each of the following techniques:

- 11 -


•	Income approach, which is based on the present value of a future stream of net cash flows.


•	Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.

As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows:


•	Level 1 - Quoted prices for identical assets or liabilities in active markets.


•	Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means.


•	Level 3 - Unobservable inputs that reflect estimates and assumptions.

The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:



	As of September 30, 2017						As of December 31, 2016
Fair Value Measurements:	Level 1		Level 2		Level 3		Level 1		Level 2		Level 3

Marketable securities (see Note 4)
Equity securities	$	454	$	—	$	—	$	4,033	$	—	$	—
Money market funds	44,312		—		—		—		—		—
Corporate bonds	—		18,986		—		—		57,348		—
Government securities - U.S.	—		11,133		—		—		42,814		—
Government securities - Non-U.S.	—		69		—		—		233		—
Other fixed-income securities	—		3,207		—		—		10,471		—
Other securities	—		—		—		—		81		—
Total assets	$	44,766	$	33,395	$	—	$	4,033	$	110,947	$	—

Related party payables (see Note 7)	—		—		107,117		—		—		169,347
Total liabilities	$	—	$	—	$	107,117	$	—	$	—	$	169,347

A review of fair value hierarchy classifications is conducted on a quarterly basis. Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the periods ended September 30, 2017 and December 31, 2016, there were no transfers into and out of Level 1, 2, or 3. During the three and nine month periods ended September 30, 2017 and 2016, we did not recognize any other-than-temporary impairment loss.

Some of the Company's financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the balance sheet at carrying value, which approximates fair value due to their short-term nature. Additionally, the Company's long-term debt is reflected in the balance sheet at carrying value, which approximates fair value, as these represent non-interest bearing grants from the French government and are repayable only if the research project is technically or commercially successful.

NOTE 4 : Marketable Securities

The Company has investments in available-for-sale marketable securities which are recorded at fair market value. Unrealized gains and losses are recorded as other comprehensive income (loss) in shareholders’ equity, net of income tax effects.

- 12 -

The following tables show the Company’s available-for-sale securities’ adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of September 30, 2017 and December 31, 2016, respectively:



	As of September 30, 2017
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	438	$	26	$	(10	)	$	454
Money market funds	44,311		1		—			44,312
Corporate bonds	19,014		84		(112		)	18,986
Government securities - U.S.	11,220		21		(108		)	11,133
Government securities - Non-U.S.	70		—		(1		)	69
Other fixed-income securities	3,212		—		(5		)	3,207
Total	$	78,265	$	132	$	(236	)	$	78,161



	As of December 31, 2016
Marketable Securities:	Adjusted Cost		Unrealized Gains		Unrealized Losses			Fair Value

Equity securities	$	3,689	$	409	$	(65	)	$	4,033
Corporate bonds	57,871		89		(612		)	57,348
Government securities - U.S.	43,049		515		(750		)	42,814
Government securities - Non-U.S.	247		—		(14		)	233
Other fixed-income securities	10,281		221		(31		)	10,471
Other securities	81		—		—			81
Total	$	115,218	$	1,234	$	(1,472	)	$	114,980

We determine realized gains or losses on the sale of marketable securities on a specific identification method. We recognized gross realized gains of $2,978 and $635 for the three months ended September 30, 2017, and 2016, respectively. These realized gains were offset by realized losses of $2,432 and $756 for the three months ended September 30, 2017, and 2016, respectively. We recognized gross realized gains of $4,228 and $709 for the nine months ended September 30, 2017, and 2016, respectively. These realized gains were offset by realized losses of $3,755 and $1,430 for the nine months ended September 30, 2017, and 2016, respectively. We reflect these gains and losses as a component of investment income in the accompanying condensed consolidated statements of income (loss).

The following table summarizes the estimated fair value of our investments in marketable debt securities, accounted for as available-for-sale securities and classified by the contractual maturity date of the securities as of September 30, 2017:



	Maturities
Marketable Debt Securities:	Less than 1 Year		1-5 Years		5-10 Years		Greater than 10 Years		Total

Corporate bonds	1,361		16,219		1,136		270		18,986
Government securities - U.S.	172		8,547		348		2,066		11,133
Government securities - Non-U.S.	—		—		69		—		69
Other fixed-income securities	—		2,473		734		—		3,207
Total	$	1,533	$	27,239	$	2,287	$	2,336	$	33,395

The Company has classified our investment in available-for-sale marketable securities as current assets in the condensed consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in our investment portfolio.

- 13 -

NOTE 5 : Inventories

The principal categories of inventories, net of reserves of $2,039 and $3,223 at September 30, 2017 and December 31, 2016, respectively, are comprised of the following:



Inventory:	September 30, 2017		December 31, 2016

Finished goods	$	4,605	$	2,429
Raw materials	1,265		829
Total	$	5,870	$	3,258

NOTE 6 : Goodwill and Intangible Assets

The Company's amortizable and unamortizable intangible assets at September 30, 2017 and December 31, 2016 are as follows:



	As of September 30, 2017							As of December 31, 2016
Goodwill and Intangible Assets:	Gross Value		Accumulated Amortization			Net Carrying Amount		Gross Value		Accumulated Amortization			Net Carrying Amount

Amortizable intangible assets:
Acquired developed technology - Noctiva	$	73,111	$	—		$	73,111	$	—	$	—		$	—
Acquired developed technology - Vazculep	12,061		(9,411		)	2,650		12,061		(8,801		)	3,260
Acquired product marketing rights	16,600		(1,854		)	14,746		16,600		(1,019		)	15,581
Acquired developed technology	4,300		(551		)	3,749		4,300		(304		)	3,996
Total amortizable intangible assets	$	106,072	$	(11,816	)	$	94,256	$	32,961	$	(10,124	)	$	22,837

Unamortizable intangible assets:
Goodwill	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491
Total unamortizable intangible assets	$	18,491	$	—		$	18,491	$	18,491	$	—		$	18,491

The Company recorded amortization expense related to amortizable intangible assets of $564 and $3,702 for the three months ended September 30, 2017 and 2016, respectively. The Company recorded amortization expense related to amortizable intangible assets of $1,692 and $10,918 for the nine months ended September 30, 2017 and 2016, respectively.

During the period, the Company acquired $73,111 in developed technology as part of the ELAA with Serenity Pharmaceuticals, LLC. The aggregate cost was composed of an upfront payment of $50,000, an accrued payment of $20,000 due within one year, and $3,111 of transaction costs. The Company will amortize the developed technology over a 13 year period beginning October 1, 2017.

Amortizable intangible assets are amortized over their estimated useful lives, which range from three to fifteen years. Estimated amortization of intangible assets for the next five years is as follows:



Estimated Amortization Expense:	Amount

2017	$	3,664
2018	7,882
2019	7,882
2020	7,882
2021	7,067

- 14 -

NOTE 7 : Long-Term Related Party Payable

Long-term related party payable and related activity are reported at fair value and consist of the following for the three months ended September 30, 2017:



				Activity during the Three Months Ended September 30, 2017
								Changes in Fair Value of Related Party Payable
Long-Term Related Party Payable:	Balance, June 30, 2017				Payments to Related Parties			Operating Expense / (Income)			Other Expense / (Income)			Balance, September 30, 2017

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	10,400			$	—		$	(2,173	)	$	—		$	8,227
Earn-out payments - Éclat Pharmaceuticals (b)	84,094				(8,214		)	(7,685		)	—			68,195
Royalty agreement - FSC (c)	8,010				(296		)	(48		)	—			7,666
Financing-related:
Royalty agreement - Deerfield (d)	6,743				(784		)	—			(520		)	5,439
Royalty agreement - Broadfin (e)	3,212				(374		)	—			(248		)	2,590
Long-term liability - FSC (f)	15,000				—			—			—			15,000
Total related party payable	127,459				$	(9,668	)	$	(9,906	)	$	(768	)	107,117
Less: Current portion	(40,615		)											(30,986		)
Total long-term related party payable	$	86,844												$	76,131

Long-term related party payable and related activity are reported at fair value and consist of the following for the nine months ended September 30, 2017:



				Activity during the Nine Months Ended September 30, 2017
								Changes in Fair Value of Related Party Payable
Long-Term Related Party Payable:	Balance, December 31, 2016				Payments to Related Parties			Operating Expense / (Income)			Other Expense / (Income)			Balance, September 30, 2017

Acquisition-related contingent consideration:
Warrants - Éclat Pharmaceuticals (a)	$	11,217			$	—		$	(2,990	)	$	—		$	8,227
Earn-out payments - Éclat Pharmaceuticals (b)	121,377				(24,729		)	(28,453		)	—			68,195
Royalty agreement - FSC (c)	7,291				(961		)	1,336			—			7,666
Financing-related:
Royalty agreement - Deerfield (d)	9,794				(2,332		)	—			(2,023		)	5,439
Royalty agreement - Broadfin (e)	4,668				(1,113		)	—			(965		)	2,590
Long-term liability - FSC (f)	15,000				—			—			—			15,000
Total related party payable	169,347				$	(29,135	)	$	(30,107	)	$	(2,988	)	107,117
Less: Current portion	(34,177		)											(30,986		)
Total long-term related party payable	$	135,170												$	76,131

(a)

As part of the consideration for the Company’s acquisition of Éclat on March 13, 2012, the Company issued two warrants to a related party with a six-year term which allow for the purchase of a combined total of 3,300 ordinary shares of Avadel. One warrant is exercisable for 2,200 shares at an exercise price of $7.44 per share, and the other warrant is exercisable for 1,100 shares at an exercise price of $11.00 per share.

- 15 -

The fair value of the warrants is estimated on a quarterly basis using a Black-Scholes option pricing model with the following assumptions as of September 30:



Assumptions for the Warrant Valuation:	September 30, 2017			September 30, 2016

Stock price	$	10.50		$	12.40
Weighted average exercise price per share	8.63			8.63
Expected term (years)	0.50			1.50
Expected volatility	40.30		%	58.40		%
Risk-free interest rate	1.20		%	0.68		%
Expected dividend yield	—			—

These Black-Scholes fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. The fair value of the warrant consideration is most sensitive to movement in the Company’s share price and expected volatility at the balance sheet date.

Expected term: The expected term of the options or warrants represents the period of time between the grant date and the time the options or warrants are either exercised or forfeited, including an estimate of future forfeitures for outstanding options or warrants. Given the limited historical data and the grant of stock options and warrants to a limited population, the simplified method has been used to calculate the expected life.

Expected volatility: The expected volatility is calculated based on an average of the historical volatility of the Company's stock price.

Risk-free interest rate: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.

Expected dividend yield: The Company has not distributed any dividends since our inception and has no plan to distribute dividends in the foreseeable future.

At the closing date of the 2012 Éclat acquisition and at September 30, 2017, it was uncertain as to whether the Company would ultimately fulfill our obligation under these warrants using Company shares or cash. Accordingly, pursuant to the guidance of ASC 480, the Company determined that these warrants should be classified as a liability. This classification as a liability was further supported by the Company’s determination, pursuant to the guidance of ASC 815-40-15-7(i), that these warrants could also not be considered as being indexed to the Company’s own stock, on the basis that the exercise price for the warrants is determined in U.S. dollars, although the functional currency of the Company at the closing date of the Éclat acquisition was the Euro.

(b)

In March 2012, the Company acquired all of the membership interests of Éclat from Breaking Stick Holdings, L.L.C. (“Breaking Stick”, formerly Éclat Holdings), an affiliate of Deerfield. Breaking Stick is majority owned by Deerfield, with a minority interest owned by the Company’s CEO, and certain other current and former employees. As part of the consideration, the Company committed to provide quarterly earn-out payments equal to 20% of any gross profit generated by certain Éclat products. These payments will continue in perpetuity, to the extent gross profit of the related products also continue in perpetuity.


(c)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part included a commitment to pay quarterly a 15% royalty on the net sales of certain FSC products, up to $12,500 for a period not exceeding ten years.

(d)

As part of a February 2013 debt financing transaction conducted with Deerfield, the Company received cash of $2,600 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 1.75% royalty on the net sales of certain Éclat products until December 31, 2024. In connection with such debt financing transaction, the Company granted Deerfield a security interest in the product registration rights of the Eclat products.


(e)	As part of a December 2013 debt financing transaction conducted with Broadfin Healthcare Master Fund, a related party and current shareholder, the Company received cash of $2,200 in exchange for entering into a royalty agreement whereby the Company shall pay quarterly a 0.834% royalty on the net sales of certain Éclat products until December 31, 2024.

- 16 -


(f)	In February 2016, the Company acquired all of the membership interests of FSC from Deerfield. The consideration for this transaction in part consists of payments totaling $1,050 annually for five years with a final payment in January 2021 of $15,000. Substantially all of FSC's, and its subsidiaries, assets are pledged as collateral under this agreement.

At September 30, 2017, the fair value of each related party payable listed in (b) through (e) above was estimated using a discounted cash flow model based on estimated and projected annual net revenues or gross profit, as appropriate, of each of the specified Éclat and FSC products using an appropriate risk-adjusted discount rate ranging from 15% to 22%. These fair value measurements are based on significant inputs not observable in the market and thus represent a level 3 measurement as defined in ASC 820. Subsequent changes in the fair value of the acquisition-related related party payables, resulting primarily from management’s revision of key assumptions, will be recorded in the consolidated statements of income (loss) in the line items entitled "Changes in fair value of related party contingent consideration" for items noted in (b) and (c) above and in "Other income (expense) - changes in fair value of related party payable" for items (d) and (e) above. See Note 1: Summary of Significant Accounting Policies under the caption Acquisition-related Contingent Consideration and Financing-related Royalty Agreements in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K for more information on key assumptions used to determine the fair value of these liabilities.

The Company has chosen to make a fair value election pursuant to ASC 825, “Financial Instruments” for our royalty agreements detailed in items (d) and (e) above. These financing-related liabilities are recorded at fair market value on the consolidated balance sheets and the periodic change in fair market value is recorded as a component of “Other expense – changes in fair value of related party payable” on the consolidated statements of income (loss).

The following table summarizes changes to the related party payables, a recurring Level 3 measurement, for the nine-month periods ended September 30, 2017 and 2016, respectively:



Related Party Payable Rollforward:	Balance

Balance at December 31, 2015	$	122,693
Additions ⁽²⁾	22,695
Payment of related party payables	(24,227		)
Fair value adjustments ⁽¹⁾	59,124
Balance at September 30, 2016	180,285

Balance at December 31, 2016	169,347
Payment of related party payable	(29,135		)
Fair value adjustments ⁽¹⁾	(33,095		)
Balance at September 30, 2017	$	107,117

⁽¹⁾Fair value adjustments are reported as Changes in fair value of related party contingent consideration and Other income (expense) - changes in fair value of related party payable in the Condensed Consolidated Statements of Income (Loss).

⁽²⁾Relates to the acquisition of FSC. See items (c) and (f) above.

NOTE 8 : Income Taxes

The components of income (loss) before income taxes are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Income (Loss) Before Income Taxes:	2017			2016			2017			2016

Ireland	$	(6,111	)	$	(3,485	)	$	1,924		$	(17,413	)
United States	29,627			(6,814		)	96,288			4,948
France	3,313			(6,244		)	(1,950		)	(15,333		)
Other	771			—			2,084			—
Total income before income taxes	$	27,600		$	(16,543	)	$	98,346		$	(27,798	)

- 17 -

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company's effective tax rate are as follows:



	Three Months Ended September 30,						Nine Months Ended September 30,
Income Tax Rate Reconciliation:	2017			2016			2017			2016

Statutory tax rate	12.5		%	33.3		%	12.5		%	33.3		%
International tax rates differential	24.9		%	(3.6		)%	20.5		%	(13.3		)%
Valuation allowance on net operating loss	(1.6		)%	(2.0		)%	0.5		%	(15.3		)%
Nondeductible change in fair value of contingent consideration	(12.8		)%	(38.9		)%	(10.9		)%	(62.0		)%
Other	(1.6		)%	(9.6		)%	(0.3		)%	(8.2		)%
Effective income tax rate	21.4		%	(20.8		)%	22.3		%	(65.5		)%

Income tax provision - at statutory tax rate	$	3,449		$	(5,509	)	$	12,294		$	(9,257	)
International tax rates differential	6,861			591			20,120			3,706
Valuation allowance on net operating loss	(438		)	339			476			4,252
Nondeductible change in fair value of contingent consideration	(3,521		)	6,436			(10,751		)	17,236
Other	(430		)	1,594			(309		)	2,275
Income tax provision - at effective income tax rate	$	5,921		$	3,451		$	21,830		$	18,212

In 2016, we changed our jurisdiction of incorporation from France to Ireland by merging with and into our wholly owned Irish subsidiary. Accordingly, beginning in the fourth quarter of 2016, the Company reports the Irish tax jurisdiction as our domestic jurisdiction. For periods prior to the fourth quarter of 2016, the French tax jurisdiction was the domestic jurisdiction.

The income tax provision for the three months ended September 30, 2017 and 2016 was $5,921 and $3,451, respectively. The increase in the income tax provision for the three months ended September 30, 2017 is primarily the result of increases in income in the United States, which was partially offset by a reduction in the amount of nondeductible contingent consideration.

The income tax provision for the nine months ended September 30, 2017 and 2016 was $21,830 and $18,212, respectively. The increase in the income tax provision for the nine months ended September 30, 2017 is primarily the result of increases in income in the United States and Ireland, which was partially offset by a reduction in the amount of nondeductible contingent consideration.

NOTE 9 : Other Assets and Liabilities

Various other assets and liabilities are summarized as follows:



Prepaid Expenses and Other Current Assets:	September 30, 2017		December 31, 2016

Valued-added tax recoverable	$	1,049	$	736
Prepaid expenses	1,002		3,442
Advance to suppliers and other current assets	726		1,265
Income tax receivable	596		451
Total	$	3,373	$	5,894



Other Non-Current Assets:	September 30, 2017		December 31, 2016

Deferred tax assets	$	7,110	$	7,432
Other	1,910		99
Total	$	9,020	$	7,531

- 18 -



Accrued Expenses:	September 30, 2017		December 31, 2016

Accrued compensation	$	3,456	$	3,291
Accrued social charges	827		794
Accrued employee severance (see Note 10)	1,926		—
Customer allowances	13,453		7,981
Accrued amounts due to contract research organization	1,472		1,764
Accrued ELAA payment	20,000		—
Accrued CMO charges	2,380		936
Other	4,483		2,456
Total	$	47,997	$	17,222



Other Non-Current Liabilities:	September 30, 2017		December 31, 2016

Provision for retirement indemnity	$	2,137	$	2,431
Customer allowances	1,883		905
Unrecognized tax benefits	2,456		1,565
Other	435		374
Total	$	6,911	$	5,275

NOTE 10 : Restructuring Costs

During the first quarter of 2017, the Company announced a plan to reduce our workforce at our Lyon, France site by approximately 50%. This reduction is an effort to align the Company's cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council and received approval from the French Labor Commission (DIRECCTE) to implement the plan. The reduction is substantially complete at the end of the third quarter. However, the Company expects to incur other cost of up to approximately $500, which are likely to be recognized through the first half of 2018. Restructuring income of $549 and charges of $3,173 were recognized during the three and nine months ended September 30, 2017. No similar amounts were recorded during the three and nine months ended September 30, 2016. The restructuring income resulted from a retirement indemnity curtailment gain of $549 in the three months ended September 30, 2017 associated with the reduction of certain defined benefit retirement plan liabilities due to the reduction in force.

The following table sets forth activities for the Company’s cost reduction plan obligations for the nine months ended September 30, 2017. There were no restructuring related charges in the nine months ended September 30, 2016:



Severance Obligation:	2017

Balance of accrued costs at January 1,	$	—
Charges for employee severance, benefits and other	3,722
Payments	(2,164		)
Foreign currency impact	368
Balance of accrued costs at September 30,	$	1,926

Total accrued employee severance in the Company’s condensed consolidated balance sheet at September 30, 2017 is included under current liabilities in “Accrued expenses.”

NOTE 11 : Net Income (Loss) Per Share

Basic net income (loss) per share is calculated using the weighted average number of shares outstanding during each period. The diluted net income (loss) per share calculation includes the impact of dilutive equity compensation awards and contingent consideration warrants.

- 19 -

A reconciliation of basic and diluted net income (loss) per share, together with the related shares outstanding in thousands is as follows:



	Three Months Ended September 30,					Nine Months Ended September 30,
Net Income (Loss) Per Share:	2017		2016			2017		2016

Net income (loss)	$	21,679	$	(19,994	)	$	76,516	$	(46,010	)

Weighted average shares:
Basic shares	40,061		41,241			40,839		41,241
Effect of dilutive securities—options and warrants outstanding	1,278		—			1,355		—
Diluted shares	41,339		41,241			42,194		41,241

Net income (loss) per share - basic	$	0.54	$	(0.48	)	$	1.87	$	(1.12	)
Net income (loss) per share - diluted	$	0.52	$	(0.48	)	$	1.81	$	(1.12	)

Potential common shares of 5,008 and 6,860 were excluded from the calculation of weighted average shares for the three months ended September 30, 2017 and 2016, respectively, because their effect was considered to be anti-dilutive. Potential common shares of 5,086 and 6,860 were excluded from the calculation of weighted average shares for the nine months ended September 30, 2017 and 2016, respectively, because their effect was considered to be anti-dilutive.

NOTE 12 : Comprehensive Income (Loss)

The following table shows the components of accumulated other comprehensive loss for the three and nine months ended September 30, 2017 and 2016, respectively, net of tax effects:



	Three Months Ended September 30,						Nine Months Ended September 30,
Accumulated Other Comprehensive Loss:	2017			2016			2017			2016

Foreign currency translation adjustment:
Beginning balance	$	(23,089	)	$	(19,952	)	$	(23,336	)	$	(22,312	)
Foreign currency translation gain (loss)	(229		)	1,567			18			3,927
Balance at September 30,	$	(23,318	)	$	(18,385	)	$	(23,318	)	$	(18,385	)

Unrealized gain (loss) on marketable securities, net
Beginning balance	$	409		$	1,102		$	(229	)	$	(345	)
Net other comprehensive income (loss), net of $92, $152, $0 and ($49) tax, respectively	(512		)	(2,405		)	126			(958		)
Balance at September 30,	$	(103	)	$	(1,303	)	$	(103	)	$	(1,303	)
Accumulated other comprehensive loss at September 30,	$	(23,421	)	$	(19,688	)	$	(23,421	)	$	(19,688	)

The effect on the Company’s condensed consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.

- 20 -

NOTE 13 : Shareholders’ Equity

The following table presents a reconciliation of the Company’s beginning and ending balances in shareholders’ equity for the nine months ended September 30, 2017:



Shareholders' Equity:	2017

Shareholders' equity - January 1,	$	42,069
Net income	76,516
Adjustment to accumulated deficit (see Note 2)	(11,156		)
Other comprehensive income	144
Stock option exercised	377
Stock-based compensation expense	6,019
Share repurchases	(17,506		)
Shareholders' equity - September 30,	$	96,463

Share Repurchases

In March 2017, the Board of Directors approved an authorization to repurchase up to $25,000 of Avadel ordinary shares represented by American Depositary Shares. Under this authorization, which has an indefinite duration, share repurchases may be made in the open market, in block transactions on or off the exchange, in privately negotiated transactions, or through other means as determined by the Board of Directors and in accordance with the regulations of the Securities and Exchange Commission. The timing and amount of repurchases, if any, will depend on a variety of factors, including the price of our shares, cash resources, alternative investment opportunities, corporate and regulatory requirements and market conditions. This share repurchase program may be modified, suspended or discontinued at any time without prior notice. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. As of September 30, 2017, the Company had repurchased 1,673 ordinary shares for $17,506, of which $799 remained unsettled within accounts payable at September 30, 2017.

NOTE 14 : Company Operations by Product

The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on our proprietary polymer based technology. The Company's Chief Operating Decision Maker is the CEO. The CEO and the Board review profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations. All products are included in one segment because the majority of the Company's products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.

The following table presents a summary of total revenues by these products:



	Three Months Ended September 30,				Nine Months Ended September 30,
Revenues by Product:	2017		2016		2017		2016

Bloxiverz	$	9,920	$	15,591	$	37,541	$	65,958
Vazculep	9,573		9,340		29,906		29,167
Akovaz	18,561		5,568		65,110		5,568
Other	1,093		841		5,452		4,165
Total product sales and services	39,147		31,340		138,009		104,858
License and research revenue	528		747		484		2,303
Total revenues	$	39,675	$	32,087	$	138,493	$	107,161

- 21 -

NOTE 15 : Commitments and Contingencies

Litigation

The Company is subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At September 30, 2017 and December 31, 2016, there were no contingent liabilities with respect to any threat of litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Material Commitments

The Company has a commitment to purchase finished product from a contract manufacturer for a six-year period commencing in 2018. Commitments for this arrangement, at maximum quantities and at contractual prices over the remaining life of the contract, and excluding any waived commitments, are as follows for the years ended December 31:



Purchase Commitment:	Balance

2018	$	3,241
2019	3,704
2020	3,704
2021	3,704
2022	3,704
Thereafter	3,704
Total	$	21,761

Other than commitments disclosed in Note 14 - Contingent Liabilities and Commitments to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K and those noted above, there were no other material commitments outside of the normal course of business. Material commitments in the normal course of business include long-term debt and post-retirement benefit plan obligations which are disclosed in Note 9 - Long-Term Debt and Note 12 – Post-Retirement Benefit Plans, respectively, to the Company's consolidated financial statements included in Part II, Item 8 of the Company’s 2016 Annual Report on Form 10-K and long-term contingent consideration payable as disclosed in Note 7 – Long-Term Related Party Payable, to the Company's condensed consolidated financial statements included in Part I, Item 1 of this report.

- 22 -

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis

(In thousands, except per share data)

(Unaudited)

You should read the discussion and analysis of our financial condition and results of operations set forth in this Item 2 together with our condensed consolidated financial statements and the related notes appearing elsewhere in this quarterly report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties, and reference is made to the “Cautionary Disclosure Regarding Forward-Looking Statements” set forth immediately following the Table of Contents of the Company’s 2016 Annual Report on Form 10-K filed with the SEC on March 28, 2017 (the “2016 Annual Report”) for further information on the forward-looking statements herein. In addition, you should read the “Risk Factors” section in Part I, Item 1A of the 2016 Annual Report for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this quarterly report.

Overview

Nature of Operations

Avadel Pharmaceuticals plc (“Avadel,” the “Company,” “we,” “our,” or “us”) is a specialty pharmaceutical company engaged in identifying, developing, and commercializing niche branded pharmaceutical products mainly in the U.S. Our business model consists of three distinct strategies:

•

the development of differentiated, patent protected products through application of the Company’s proprietary patented drug delivery platforms, Micropump® and LiquiTime®, that target high-value solid and liquid oral and alternative dosages forms through the U.S. Food and Drug Administration (FDA) 505(b)(2) approval process, which allows a sponsor to submit an application that doesn’t depend on efficacy, safety, and toxicity data created by the sponsor. In addition to Micropump® and LiquiTime®, the Company has two other proprietary drug delivery platforms, Medusa™ (hydrogel depot technology for use with large molecules and peptides) and Trigger Lock™ (controlled release of opioid analgesics with potential abuse deterrent properties).

•

the identification of Unapproved Marketed Drugs (“UMDs”), which are currently sold in the U.S., but unapproved by the FDA, and the pursuit of approval for these products via a 505(b)(2) New Drug Application (NDA). To date, the Company has received approvals through this “unapproved-to-approved” avenue for three products: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). As a potential source of near-term revenue growth, Avadel is working on the development of a fourth product for potential NDA submission and seeks to identify additional product candidates for development with this strategy.

•

the acquisition of commercial and or late-stage products or businesses. On September 1, 2017, the Company entered into an Exclusive License and Assignment Agreement ("ELAA") with Serenity Pharmaceuticals, LLC . The ELAA grants the Company the sole right to commercialize and further develop Noctiva™ in the United States. Noctiva is a proprietary low-dose formulation of desmopressin acetate administered through a patent-protected intranasal delivery system. It is the first and only product approved by the U.S. Food and Drug Administration (“FDA”) for the treatment of nocturia due to nocturnal polyuria. Additionally, the Company markets three branded pediatric-focused pharmaceutical products in the primary care space, and a 510(k) approved device all of which were purchased through the acquisition of FSC Laboratories and FSC Pediatrics ("FSC") on February 5, 2016. We will consider further acquisitions and the Company continues to look for assets that could fit strategically into our current or potential future commercial sales force.

- 23 -


•	Flamel ceased to exist as a separate entity and the Company continued as the surviving entity and assumed all of the assets and liabilities of Flamel.


•	our authorized share capital is $5,500 divided into 500,000 ordinary shares with a nominal value of $0.01 each and 50,000 preferred shares with a nominal value of $0.01 each


◦	all outstanding ordinary shares of Flamel, €0.122 nominal value per share, were canceled and exchanged on a one-for-one basis for newly issued ordinary shares of the Company, $0.01 nominal value per share. This change in nominal value of our outstanding shares resulted in our reclassifying $5,937 on our balance sheet from ordinary shares to additional paid-in capital

◦


•	all outstanding American Depositary Shares (ADSs) representing ordinary shares of Flamel were canceled and exchanged on a one-for-one basis for ADSs representing ordinary shares of the Company.

Strategy

The Company's business strategy is designed to drive overall sales and earnings growth while maintaining a return on invested capital at an appropriate premium above the Company's cost of capital. Our key areas of focus address the most significant opportunities and challenges we face, including:

•

Unapproved to Approved Marketed Drug Development: The Company derives a majority of its sales and cash flow from FDA approvals through this “unapproved-to-approved” strategy for three products: Bloxiverz® (neostigmine methylsulfate injection), Vazculep® (phenylephrine hydrochloride injection) and Akovaz® (ephedrine sulfate injection). During the three months ended September 30, 2017 the Company generated $38,054 of sales from these products compared to $30,499 in the same period of 2016, respectively. During the nine months ended September 30, 2017 the Company generated $132,557 of sales from these products compared to $100,693 in the same period of 2016, respectively.


◦	Bloxiverz, which had sales of $9,920 and $37,541 for the three and nine months ended September 30, 2017, respectively, was approved by the FDA on May 31, 2013, and is currently being marketed in the U.S.


◦	Vazculep, which had sales of $9,573 and $29,906 for the three and nine months ended September 30, 2017, respectively, was approved by the FDA on September 27, 2014 and launched in October 2014 in the U.S.

- 24 -


◦	Akovaz, which had sales of $18,561 and $65,110 for the three and nine months ended September 30, 2017, respectively, was approved by the FDA April 29, 2016. The Company began marketing this product in August 2016.

Each of the above products is currently sold in the United States by Avadel’s subsidiary Avadel Legacy Pharmaceuticals, LLC (formerly Éclat). Through our acquisition of Éclat, we obtained marketing and licensing knowledge of the commercial and regulatory processes in the U.S. and E.U, which. we believe has enhanced our ability to identify drug product candidates for development, leverage new opportunities for the application of our drug delivery platforms, and license and market products in the U.S and E.U. The cash flow generated from these products, among other things, is used to fund our second strategy, the development and commercialization of drug delivery products.

•

Development and Commercialization of the Company’s Drug Delivery Pipeline Products: In addition to the unapproved to approved drug development strategy, the Company is continuing to advance the development of our innovative drug delivery platforms. We have enhanced our ability to identify new product candidates and to pursue commercial opportunities associated with our drug delivery platforms. The Company’s drug delivery platforms allow the creation of competitive and differentiated drug product profiles (e.g., with improved pharmacokinetics, efficacy and/or safety). We own and develop drug delivery platforms that address key formulation challenges, leading to the development of differentiated drug products for administration in various forms (e.g., capsules, tablets, sachets or liquid suspensions for oral use; or injectables for subcutaneous administration) and can be applied to a broad range of drugs (novel, already-marketed, or off-patent). Application of these technologies to pharmaceuticals allows us to protect our potential products through patent protection and product differentiation. As a result of developing our own drug delivery platforms our business is now less dependent on the development activities performed by partners, and relies more on the development of our own, self-funded, products. Our proprietary drug delivery platforms include:


◦	Micropump® is a microparticulate system that allows the development and marketing of modified and/or controlled release solid oral dosage formulations of drugs (Micropump®-carvedilol and Micropump®-aspirin formulations have been approved in the U.S. and in the E.U., respectively).


◦	LiquiTime® allows development of modified/controlled release oral products in a liquid suspension formulation particularly suited to children or patients having issues swallowing tablets or capsules. Unlike most liquid pharmaceuticals, LiquiTime® technology is not limited to ionic drugs as with resin-complex based technologies and can be applied to the development of combination products.


◦	Trigger Lock™ allows development of abuse-deterrent modified/controlled release formulations of narcotic/opioid analgesics and other drugs susceptible to abuse.


◦	Medusa™ allows the development of extended/modified release of injectable dosage formulations of drugs (e.g., peptides, polypeptides, proteins, and small molecules).

Several products formulated using our proprietary drug delivery platforms are currently under various stages of development for possible marketing either by the Company and/or by partners via licensing/distribution agreements. In particular, the Company has started a Phase III trial, titled “A Double-blind, Randomized, Placebo Controlled, Two Arm Multi-Center Study to Assess the Efficacy and Safety of a Once Nightly Formulation of Sodium Oxybate for Extended-Release Oral Suspension ("FT218") for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Subjects with Narcolepsy,” We have branded this trial REST-ON. On October 6, 2016, the Company announced that our Irish subsidiary, Avadel Ireland Holdings, has reached agreement with the U.S. Food and Drug Administration (FDA) for the design and planned analysis of the noted Phase III clinical trial of FT218, a once nightly formulation of sodium oxybate utilizing the Company’s proprietary drug delivery platform, Micropump®. The agreement was reached through the Special Protocol Assessment ("SPA") process. A SPA is an acknowledgment by FDA that the design and planned analysis of the Company’s pivotal clinical trial of FT218 adequately addresses the objectives necessary to support a regulatory submission. In December 2016, the Company initiated patient enrollment and dosing for our REST-ON Phase III clinical trial to assess the safety and efficacy of our once nightly formulation of Micropump® sodium oxybate (FT218) for the treatment of excessive daytime sleepiness ("EDS") and cataplexy in patients suffering from narcolepsy. The sole-source market for sodium oxybate, dosed twice nightly, is estimated at $1.1 billion in 2016. We believe that our product could offer significant advantages over the existing product to narcolepsy patients.

•The key elements of our pipeline strategy include:


◦	Continuing to build commercially successful products utilizing Micropump®


◦	Identifying opportunities and optimizing time-to-market for our LiquiTime® drug delivery platform;

- 25 -


◦	Maximizing the technical potential of our existing drug delivery platforms for developing new and proprietary products; and


◦	Developing and validating improved and complementary drug delivery platforms related to our current drug delivery capabilities.

•

Inorganic growth through Acquisitions and/or Partnerships: The Company maintains a strong balance sheet with substantial liquidity and no bank debt. As part of our overall enterprise strategy, the Company expects to explore and pursue appropriate inorganic growth opportunities that complement our drug delivery platforms or to acquire proprietary products that enhance profitability and cash flow. This was evidenced in September 2017 with the execution of the ELAA with Serenity Pharmaceuticals, LLC to commercialize and further develop Noctiva in the United States. Additionally, the Company will leverage the capabilities of our existing and future proprietary products and/or drug delivery platforms with pharmaceutical and biotechnology partnerships or licensing transactions. As an example in 2015, the Company completed a licensing transaction for exclusive U.S. rights to our LiquiTime® technology-based Over-the-Counter ("OTC") products which was licensed to Elan Pharma International Limited.

•

Divestitures and out licensing: We have a stated objective to narrow our focus to our two most developed platforms, Micropump® and LiquiTime®. As a result, we are pursuing the divestiture or out licensing of Trigger Lock™ for abuse deterrence, and Medusa™ for extended-release subcutaneous injection. We believe both platforms are robust and well protected from an IP standpoint; however, their development and FDA approval will likely require substantial investments in clinical work and infrastructure, which we are not currently prepared to support.

Key Business Trends and Highlights

In operating our business and monitoring our performance, we consider a number of performance measures, as well as trends affecting our industry as a whole, which include the following:

•

Healthcare and Regulatory Reform: Various health care reform laws in the U.S. may impact our ability to successfully commercialize our products and technologies. The success of our commercialization efforts may depend on the extent to which the government health administration authorities, the health insurance funds in the E.U. Member States, private health insurers and other third party payers in the U.S. will reimburse consumers for the cost of healthcare products and services.

•

Competition and Technological Change: Competition in the pharmaceutical and biotechnology industry continues to be intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing niche branded or generic specialty pharmaceutical products or drug delivery platforms. Furthermore, major technological changes can happen quickly in the pharmaceutical and biotechnology industries. Such rapid technological change, or the development by our competitors of technologically improved or differentiated products, could render our drug delivery platforms obsolete or noncompetitive.


•	Pricing Environment for Pharmaceuticals: The pricing environment continues to be in the political spotlight in the U.S. As a result, the need to obtain and maintain appropriate pricing and reimbursement for our products may become more challenging due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the U.S. and worldwide.


•	Generics Playing a Larger Role in Healthcare: Generic pharmaceutical products will continue to play a large role in the U.S. healthcare system. Specifically, we have seen, or likely will see, additional generic competition to our current and future products and we continue to expect generic competition in the future.


•	Access to and Cost of Capital: The process of raising capital and associated cost of such capital for a company of our financial profile can be difficult and potentially expensive. If the need were to arise to raise additional capital, access to that capital may be difficult and/or expensive and, as a result, could create liquidity challenges for the Company.

Highlights of our condensed consolidated results for the three and nine months ended September 30, 2017 are as follows:


•	Revenue was $39,675 and $138,493 for the three and nine months ended September 30, 2017, compared to $32,087 and $107,161 in the same period last year, respectively. This increase was primarily the result of the launch of Akovaz in August 2016 partially offset by declines in Bloxiverz unit volumes and net selling price as a result of additional competition.


•	Operating income was $26,118 and $93,585 for the three and nine months ended September 30, 2017, compared to operating loss of $16,190 and $22,029 for the same period last year, respectively. The primary reasons for the increase

- 26 -

in operating income for the three months ended September 30, 2017 were changes in the fair value of related party contingent consideration and the gross margin on $7,807 of higher product sales and services. The company recognized a $9,906 gain resulting from changes in the fair value of related party contingent consideration for the three months ended September 30, 2017 compared to a loss of $20,848 in the same period last year. The primary reasons for the increase in operating income for the nine months ended September 30, 2017 was also due to changes in the fair value of related party contingent consideration, as well as an increased gross margin on an increase in product sales and services of $33,151 and a decrease in intangible asset amortization expense of $9,226. The company recognized a $30,107 gain resulting from changes in the fair value of related party contingent consideration for the nine months ended September 30, 2017 compared to a loss of $52,989 in the same period last year.


•	Net income was $21,679 and $76,516 for the three and nine months ended September 30, 2017, compared to a net loss of $19,994 and $46,010 in the same period last year, respectively.


•	Diluted net income per share was $0.52 and $1.81 for the three and nine months ended September 30, 2017, compared to a diluted net loss per share of $0.48 and $1.12 in the same period last year, respectively.


•	Cash and marketable securities declined $38,585 to $115,610 at September 30, 2017, from $154,195 at December 31, 2016. This decline was primarily due to $52,139 used to fund the ELAA and $16,707 for repurchases of our ordinary shares, partially offset by $30,478 in operating cash flow for the nine months ended September 30, 2017.

Critical Accounting Estimates

The Company’s condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. To prepare these financial statements, management must make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, as well as the disclosures of contingent assets and liabilities. Actual results could be significantly different from these estimates.

Our significant accounting policies are described in Note 1 of the audited consolidated financial statements included in our 2016 Form 10-K. The SEC suggests companies provide additional disclosure on those accounting policies considered most critical. The SEC considers an accounting policy to be critical if it is important to our financial condition and results of operations and requires significant judgments and estimates on the part of management in its application. Our estimates are often based on complex judgments, probabilities and assumptions that management believes to be reasonable, but that are inherently uncertain and unpredictable. It is also possible that other professionals, applying reasonable judgment to the same facts and circumstances, could develop and support a range of alternative estimated amounts. For a complete discussion of our critical accounting policies, see the “Critical Accounting Policies” section of the MD&A in our 2016 Form 10-K. There were no significant changes to our critical accounting policies during the three months ended September 30, 2017.

- 27 -

Results of Operations

The following is a summary of our financial results (in thousands, except per share amounts) for the three months ended September 30, 2017 and 2016:



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Comparative Statements of Income (Loss)	2017			2016			$			%

Product sales and services	$	39,147		$	31,340		$	7,807		24.9	%
License and research revenue	528			747			(219		)	(29.3	)%
Total revenues	39,675			32,087			7,588			23.6	%
Operating expenses:
Cost of products and services sold	3,790			2,844			946			33.3	%
Research and development expenses	8,095			8,143			(48		)	(0.6	)%
Selling, general and administrative expenses	11,563			12,740			(1,177		)	(9.2	)%
Intangible asset amortization	564			3,702			(3,138		)	(84.8	)%
(Gain) loss on changes in fair value of related party contingent consideration	(9,906		)	20,848			(30,754		)	(147.5	)%
Restructuring costs (income)	(549		)	—			(549		)	n/a
Total operating expenses	13,557			48,277			(34,720		)	(71.9	)%
Operating income (loss)	26,118			(16,190		)	42,308			261.3	%
Investment income	1,110			490			620			126.5	%
Interest expense	(263		)	(264		)	1			0.4	%
Other income (expense) - changes in fair value of related party payable	768			(1,828		)	2,596			142.0	%
Foreign exchange gain (loss)	(133		)	1,249			(1,382		)	(110.6	)%
Income (loss) before income taxes	27,600			(16,543		)	44,143			266.8	%
Income tax provision	5,921			3,451			2,470			71.6	%
Net income (loss)	$	21,679		$	(19,994	)	$	41,673		208.4	%
Income (loss) per share - diluted	$	0.52		$	(0.48	)	$	1.00		208.3	%

- 28 -

The following is a summary of our financial results (in thousands, except per share amounts) for the nine months ended September 30, 2017 and 2016:



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Comparative Statements of Income (Loss)	2017			2016			$			%

Product sales and services	$	138,009		$	104,858		$	33,151		31.6	%
License and research revenue	484			2,303			(1,819		)	(79.0	)%
Total revenues	138,493			107,161			31,332			29.2	%
Operating expenses:
Cost of products and services sold	12,253			10,657			1,596			15.0	%
Research and development expenses	22,093			21,135			958			4.5	%
Selling, general and administrative expenses	35,804			33,491			2,313			6.9	%
Intangible asset amortization	1,692			10,918			(9,226		)	(84.5	)%
Changes in fair value of related party contingent consideration	(30,107		)	52,989			(83,096		)	(156.8	)%
Restructuring costs	3,173			—			3,173			n/a
Total operating expenses	44,908			129,190			(84,282		)	(65.2	)%
Operating income (loss)	93,585			(22,029		)	115,614			524.8	%
Investment income	2,689			1,080			1,609			149.0	%
Interest expense	(789		)	(702		)	(87		)	12.4	%
Other income (expense) - changes in fair value of related party payable	2,988			(6,135		)	9,123			148.7	%
Foreign exchange loss	(127		)	(12		)	(115		)	(958.3	)%
Income (loss) before income taxes	98,346			(27,798		)	126,144			453.8	%
Income tax provision	21,830			18,212			3,618			19.9	%
Net income (loss)	$	76,516		$	(46,010	)	$	122,526		266.3	%
Income (loss) per share - diluted	$	1.81		$	(1.12	)	$	2.93		261.6	%

The revenues for each of the Company's significant products for the three months ended September 30, 2017 and 2016 are as follows:



					Three Months Ended
	Three Months Ended September 30,				Increase / (Decrease)
	Three Months Ended September 30,				2017 vs. 2016
Revenues:	2017		2016		$			%

Bloxiverz	$	9,920	$	15,591	$	(5,671	)	(36.4	)%
Vazculep	9,573		9,340		233			2.5	%
Akovaz	18,561		5,568		12,993			233.4	%
Other	1,093		841		252			30.0	%
Total product sales and services	39,147		31,340		7,807			24.9	%
License and research revenue	528		747		(219		)	(29.3	)%
Total revenues	$	39,675	$	32,087	$	7,588		23.6	%

- 29 -

Product sales and services revenues were $39,147 for the three months ended September 30, 2017 compared to $31,340 for the same prior year period. Bloxiverz’s revenue declined $5,671 when compared to the same period last year, primarily due to a loss of market share and decrease in net selling price driven largely by two factors: a) lost business as a result of a new competitor in the neostigmine market who entered the market in the first quarter of 2016 and b) a new molecule approved by the FDA in late 2015 and launched in 2016 with a similar indicated use as Bloxiverz. Vazculep’s revenue was up slightly as the phenylephrine market for which this product is used was largely unchanged. Revenue from Akovaz increased $12,993 due to its launch in August 2016. Other revenues, which includes our pediatric products, were up slightly in the third quarter of 2017 when compared to the prior year's quarter. Revenues from our pediatric products were $1,911 for the three months ended September 30, 2017, compared to $390 in the same period last year.

License and research revenue was $528 for the three months ended September 30, 2017 compared to $747 in the same period last year.

The revenues for each of the Company's significant products for the nine months ended September 30, 2017 were as follows:



					Nine Months Ended
	Nine Months Ended September 30,				Increase / (Decrease)
	Nine Months Ended September 30,				2017 vs. 2016
Revenues:	2017		2016		$			%

Bloxiverz	$	37,541	$	65,958	$	(28,417	)	(43.1	)%
Vazculep	29,906		29,167		739			2.5	%
Akovaz	65,110		5,568		59,542			1,069.4	%
Other	5,452		4,165		1,287			30.9	%
Total product sales and services	138,009		104,858		33,151			31.6	%
License and research revenue	484		2,303		(1,819		)	(79.0	)%
Total revenues	$	138,493	$	107,161	$	31,332		29.2	%

Product sales and services revenues were $138,009 for the nine months ended September 30, 2017 compared to $104,858 for the same prior year period. Revenues for the nine months ended September 30, 2016 include $5,981 in additional non-recurring revenue as a result of our change in accounting estimate previously described in our Form 10-K for the year ended December 31, 2016. Excluding the impact of this revenue change, total product sales and services for the nine months ended September 30, 2016 would have been $98,877. Bloxiverz’s revenue declined $28,417 when compared to the same period last year, primarily due to a $23,820 loss of market share and decrease in net selling price driven largely by two factors: a) lost business as a result of a new competitor in the neostigmine market who entered the market in the first quarter of 2016 and b) a new molecule approved by the FDA in late 2015 and launched in 2016 with a similar indicated use as Bloxiverz. The decline in Bloxiverz revenue was also due to the non-recurring effect of the change in the revenue estimate, noted above, of $4,597. Vazculep’s revenue was up slightly as a $2,123 increase in price and volume was partially offset by the effect of the non-recurring revenue estimate change of $1,384. Revenue from Akovaz, which was launched in August 2016, contributed $65,110 to product sales for the nine months ended September 30, 2017. Other revenues, which includes our pediatric products, were up $1,287 in the nine months ended September 30, 2017 compared to the same prior year period. Revenues from our pediatric products, which were acquired in February 2016 were $5,355 for the nine months ended September 30, 2017, compared to $2,963 in the same period last year.

License and research revenue was $484 for the nine months ended September 30, 2017 compared to $2,303 in the same period last year. In the second quarter of 2017, the Company made a determination that the performance period associated with a specific license will be longer than previously estimated and, accordingly, increased the amortization period to better match the contractual requirements of the license. Use of this longer amortization period had the effect of reducing license revenue recognized in the nine months ended September 30, 2017 by $1,819 when compared to the same period last year.

- 30 -



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Cost of Products and Services Sold:	2017			2016			$		%

Cost of products and services sold	$	3,790		$	2,844		$	946	33.3	%
Percentage of sales	9.6		%	8.9		%

Cost of products and services sold increased $946 or 33.3% during the three months ended September 30, 2017 compared to the same prior year period. As a percentage of sales, cost of products sold was up slightly to 9.6% compared to 8.9% as a result of product mix changes.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Cost of Products and Services Sold:	2017			2016			$		%

Cost of products and services sold	$	12,253		$	10,657		$	1,596	15.0	%
Percentage of sales	8.8		%	9.9		%

Cost of products and services sold increased $1,596 or 15.0% compared to the same prior year period. As a percentage of sales, cost of products sold was slighly lower than the prior year period due primarily to $1,525 of inventory reserve adjustments recorded during the first quarter of 2016 that did not recur in 2017.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Research and Development Expenses:	2017			2016			$			%

Research and development expenses	$	8,095		$	8,143		$	(48	)	(0.6	)%
Percentage of sales	20.4		%	25.4		%

Research and development expenses were largely unchanged when compared to the same period last year. The Company continues to spend a substantial portion of its research and development spending on its Phase III FT218 clinical study.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Research and Development Expenses:	2017			2016			$		%

Research and development expenses	$	22,093		$	21,135		$	958	4.5	%
Percentage of sales	16.0		%	19.7		%

Research and development expenses increased $958 as compared to the same period in 2016. This increase is due to higher spending associated with our Phase III FT218 clinical study. A substantial portion of the Company's research and development spending is associated with its Phase III FT218 clinical study.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Selling, General and Administrative Expenses:	2017			2016			$			%

Selling, general and administrative expenses	$	11,563		$	12,740		$	(1,177	)	(9.2	)%
Percentage of sales	29.1		%	39.7		%

- 31 -

Selling, general and administrative expenses decreased $1,177 during the three months ended September 30, 2017 as compared to the same prior year period. This decrease was largely due to a decrease in stock based compensation expense of $2,136 period over period, partially offset by higher payroll and benefit costs of $584 as we continue to add people to support the future growth of the business.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Selling, General and Administrative Expenses:	2017			2016			$		%

Selling, general and administrative expenses	$	35,804		$	33,491		$	2,313	6.9	%
Percentage of sales	25.9		%	31.3		%

Selling, general and administrative expenses increased $2,313 as compared to the same prior year period. This increase was primarily due to higher payroll and benefit costs of $2,813 as we continue to add people to support the future growth of the business. Additionally, we incurred higher advertising and promotion costs of $1,247 primarily associated with certain business development activities and pre-launch marketing research studies for sodium oxybate. This increase was partially offset by a decrease in stock based compensation expense of $2,971 period over period.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Intangible Asset Amortization:	2017			2016			$			%

Intangible asset amortization	$	564		$	3,702		$	(3,138	)	(84.8	)%
Percentage of sales	1.4		%	11.5		%

Intangible asset amortization expense decreased $3,138 during the three months ended September 30, 2017 as compared to the same prior year period as the Bloxiverz in process R&D asset was fully amortized as of December 31, 2016.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Intangible Asset Amortization:	2017			2016			$			%

Intangible asset amortization	$	1,692		$	10,918		$	(9,226	)	(84.5	)%
Percentage of sales	1.2		%	10.2		%

Intangible asset amortization expense decreased $9,226 compared to the same prior year period as the Bloxiverz in process R&D asset was fully amortized as of December 31, 2016.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Changes in Fair Value of Related Party Contingent Consideration:	2017			2016			$			%

(Gain)/loss - changes in fair value of related party contingent consideration	$	(9,906	)	$	20,848		$	(30,754	)	(147.5	)%
Percentage of sales	(25.0		)%	65.0		%

We compute the fair value of the related party contingent consideration using several significant assumptions and when these assumptions change, due to underlying market conditions or other factors, the fair value of these liabilities change as well.

As a result, changes in the estimates of the underlying assumptions used to determine the fair values of a) our acquisition-related contingent consideration earn-out payments - Éclat, b) acquisition related warrants and c) acquisition related FSC royalty liabilities we recorded a gain of $9,906 to reduce the fair value of these liabilities in the third quarter of 2017 compared to an expense of

- 32 -

$20,848 to increase the fair value of these liabilities in the third quarter of 2016. As noted in our critical accounting estimates, described in our December 31, 2016 Form 10-K, there are numerous estimates we use when determining the fair value of the acquisition-related earn-out payments - Éclat. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows.

For the three months ended September 30, 2017, as a result of changes to these estimates when compared to these same estimates at June 30, 2017, we recognized a gain of $7,685 to lower the fair value of acquisition related liabilities for the Éclat products primarily as a result of changes in the pricing environment for Akovaz and a weaker long-term sales and gross profit outlook for Bloxiverz due to increased competition. Additionally, we decreased the fair value of the acquisition related warrants which resulted in a gain of $2,173, primarily due to changes in the AVDL stock price at September 30, 2017 compared to June 30, 2017, changes in the volatility of AVDL stock and a shorter remaining term of the warrants.

For the three months ended September 30, 2016, as a result of changes to these estimates when compared to the same estimates at June 30, 2016 we recognized expense of $19,720 to increase the fair value of acquisition related liabilities for the Éclat products primarily as a result at that time of a stronger long-term sales and gross profit outlook for Bloxiverz. Additionally, we increased the fair value of the acquisition related warrants which resulted in an expense of $2,058 primarily due to changes in the AVDL stock price at September 30, 2016 compared to June 31, 2016, changes in the volatility of AVDL stock, partiality offset by a shorter remaining term of the warrants.

Each of the underlying assumptions used to determine the fair values of these contingent liabilities can, and often do, change based on adjustments in current market conditions, competition and other factors. These changes can have a material impact on our consolidated statements of income (loss), balance sheet and cash flows.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Changes in Fair Value of Related Party Contingent Consideration:	2017			2016			$			%

(Gain)/ loss - changes in fair value of related party contingent consideration	$	(30,107	)	$	52,989		$	(83,096	)	(156.8	)%
Percentage of sales	(21.7		)%	49.4		%

We compute the fair value of the related party contingent consideration using several significant assumptions and when these assumptions change, due to underlying market conditions the fair value of these liabilities change as well.

As a result changes in the estimates of the underlying assumptions used to determine the fair values of a) our acquisition-related contingent consideration earn-out payments - Éclat, b) acquisition related warrants and c) acquisition related FSC royalty liabilities we recorded a gain of $30,107 to reduce the fair value of these liabilities for the nine months ended September 30, 2017 compared to an expense of $52,989 to increase the fair value of these liabilities for the nine months ended September 30, 2016. As noted in our critical accounting estimates, there are numerous estimates we use when determining the fair value of the acquisition-related earn-out payments - Éclat. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve, the cost of goods related to such products and an appropriate discount rate to use when present valuing the related cash flows.

For the nine months ended September 30, 2017, as a result of changes to these estimates when compared to the same estimates at December 31, 2016, we recognized a gain of $28,453 to lower the fair value of acquisition related liabilities for the Éclat products primarily as a result of changes in the pricing environment for Akovaz and a weaker long-term sales and gross profit outlook for Bloxiverz due to more competition. Additionally, we decreased the fair value of the acquisition related warrants which resulted in a gain of of $2,990, primarily due to changes in the AVDL stock price at September 30, 2017 compared to December 31, 2016, changes in the volatility of AVDL stock, partially offset by a shorter remaining term of the warrants.

For the nine months ended September 30, 2016, as a result of changes to these estimates when compared to the same estimates at December 31, 2015 we recognized expense of $58,081 to increase the fair value of acquisition related liabilities for the Éclat products primarily as a result at that time of a stronger long-term sales and gross profit outlook for Bloxiverz. Additionally, we reduced the fair value of the acquisition related warrants which resulted in a gain of $3,097 primarily due to changes in the AVDL stock price at September 30, 2016 compared to December 31, 2015, changes in the volatility of AVDL stock partially offset by a shorter remaining term of the warrants.

- 33 -



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Restructuring Costs	2017			2016			$			%

Restructuring (income) costs	$	(549	)	$	—		$	(549	)	n/a
Percentage of sales	(1.4		)%	—		%

We recorded a reduction of $549 in restructuring charges during the three months ended September 30, 2017. During the first quarter of 2017, we announced a plan to reduce our workforce at our Lyon, France site by approximately 50%. This reduction is an effort to align the Company's cost structure with our ongoing and future planned projects. In July 2017, the Company completed negotiations with the works council and received approval from the French Labor Commission to implement the plan. The reduction was substantially complete at the end of the third quarter. However, the Company expects to incur additional restructuring costs of up to approximately $500, which are likely to be recognized through the first half of 2018. The Company recorded a curtailment gain of $549 in the three months ended September 30, 2017 associated with the reduction of certain defined benefit retirement plan liabilities due to the reduction in force.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Restructuring Costs	2017			2016			$		%

Restructuring costs	$	3,173		$	—		$	3,173	n/a
Percentage of sales	2.3		%	—		%

Restructuring charges of $3,173 were recognized during the nine months ended September 30, 2017 associated with the workforce reduction noted above.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Other Income (Expense) - Changes in Fair Value of Related Party Payable	2017			2016			$		%

Changes in fair value of related party payable	$	768		$	(1,828	)	$	2,596	142.0	%
Percentage of sales	1.9		%	(5.7		)%

We recorded a gain of $768 to reduce the fair value of related party payables during the three months ended September 30, 2017 due to the same reasons associated with the Éclat product sales described in the section Changes in fair value of related party contingent consideration for this period. As noted in our critical accounting estimates described in the December 31, 2016 Form 10-K, there are a number of estimates we use when determining the fair value of the related party payable payments. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates can and often do change based on changes in current market conditions, competition and other factors.

We recorded expense of $1,828 to increase the fair value of these liabilities during the three months ended September 30, 2016 due to the same reasons associated with the Éclat product sales described in the section Changes in fair value of related party contingent consideration for this period. As noted in our critical accounting estimates, there are a number of estimates we use when determining the fair value of the related party payable payments. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates can and often do change based on changes in current market conditions, competition and other factors.

- 34 -



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Other Income (Expense) - Changes in Fair Value of Related Party Payable	2017			2016			$		%

Changes in fair value of related party payable	$	2,988		$	(6,135	)	$	9,123	148.7	%
Percentage of sales	2.2		%	(5.7		)%

We recorded a gain of $2,988 to reduce the fair value of these liabilities during the nine months ended September 30, 2017 due to the same reasons associated with the Éclat product sales described in the section Changes in fair value of related party contingent consideration for this period. As noted in our critical accounting estimates described in the December 31, 2016 Form 10-K, there are a number of estimates we use when determining the fair value of the related party payable payments. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates can and often do change based on changes in current market conditions, competition and other factors.

We recorded expense of $6,135 to increase the fair value of these liabilities during the nine months ended September 30, 2016 due to the same reasons associated with the Éclat product sales described in the section Changes in fair value of related party contingent consideration for this period. As noted in our critical accounting estimates, there are a number of estimates we use when determining the fair value of the related party payable payments. These estimates include the long-term pricing environment, market size, the market share the related products are forecast to achieve and an appropriate discount rate to use when present valuing the related cash flows. These estimates can and often do change based on changes in current market conditions, competition and other factors.



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Investment Income:	2017			2016			$		%

Investment income	$	1,110		$	490		$	620	126.5	%
Percentage of sales	2.8		%	1.5		%

Investment income increased $620 during the three months ended September 30, 2017 as compared to the same prior year period as gains were realized on a higher volume of sales of marketable securities period over period.



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Investment Income:	2017			2016			$		%

Investment income	$	2,689		$	1,080		$	1,609	149.0	%
Percentage of sales	1.9		%	1.0		%

Investment income increased $1,609 during the nine months ended September 30, 2017 as compared to the same prior year period as gains were realized on a higher volume of sales of marketable securities period over period.

- 35 -



							Three Months Ended
	Three Months Ended September 30,						Increase / (Decrease)
	Three Months Ended September 30,						2017 vs. 2016
Income Tax Provision:	2017			2016			$		%

Income tax provision	$	5,921		$	3,451		$	2,470	71.6	%
Percentage of income (loss) before income taxes	21.5		%	(20.9		)%

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company's effective tax rate for the three months ended September 30, 2017 and 2016, are as follows:



	Three Months Ended September 30,
	2017			2016

Statutory tax rate	12.5		%	33.3		%
International tax rates differential	24.9		%	(3.6		)%
Valuation allowance on net operating losses	(1.6		)%	(2.0		)%
Nondeductible contingent consideration	(12.8		)%	(38.9		)%
Other	(1.6		)%	(9.6		)%
Effective income tax rate	21.4		%	(20.8		)%

Income tax provision - at statutory tax rate	$	3,449		$	(5,509	)
International tax rates differential	6,861			591
Valuation allowance on net operating losses	(438		)	339
Nondeductible contingent consideration	(3,521		)	6,436
Other	(430		)	1,594
Income tax provision - at effective income tax rate	$	5,921		$	3,451



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Income Tax Provision:	2017			2016			$		%

Income tax provision	$	21,830		$	18,212		$	3,618	19.9	%
Percentage of income (loss) before income taxes	22.2		%	(65.5		)%

- 36 -

The items accounting for the difference between the income tax provision computed at the statutory rate and the Company's effective tax rate for the nine months ended September 30, 2017 and 2016, are as follows:



	Nine Months Ended September 30,
	2017			2016

Statutory tax rate	12.5		%	33.3		%
International tax rates differential	20.5		%	(13.3		)%
Valuation allowance on net operating losses	0.5		%	(15.3		)%
Nondeductible contingent consideration	(10.9		)%	(62.0		)%
Other	(0.3		)%	(8.2		)%
Effective income tax rate	22.3		%	(65.5		)%

Income tax provision - at statutory tax rate	$	12,294		$	(9,257	)
International tax rates differential	20,120			3,706
Valuation allowance on net operating losses	476			4,252
Nondeductible contingent consideration	(10,751		)	17,236
Other	(309		)	2,275
Income tax provision - at effective income tax rate	$	21,830		$	18,212

Liquidity and Capital Resources

The Company's cash flows from operating, investing and financing activities, as reflected in the condensed consolidated statements of cash flows, are summarized in the following table:



							Nine Months Ended
	Nine Months Ended September 30,						Increase / (Decrease)
	Nine Months Ended September 30,						2017 vs. 2016
Net cash provided by (used in):	2017			2016			$			%

Operating activities	$	30,478		$	11,160		$	19,318		173.1	%
Investing activities	(15,167		)	(50,088		)	34,921			69.7	%
Financing activities	(17,292		)	(8,012		)	(9,280		)	(115.8	)%

Operating Activities

Net cash provided by operating activities of $30,478 for the nine months ended September 30, 2017 increased $19,318 compared to the same prior year period. This increase in operating cash flow is primarily due to higher cash earnings (net income or loss adjusted for non-cash credits and charges) of $21,755 when compared to the same period last year, largely driven from higher gross margin (revenues less cost of goods sold) on the increase in revenues. The increase in operating cash flow was partially offset by lower cash provided by changes in operating assets and liabilities of $2,437 when compared to the same period last year. Cash used for earn-out payments on related party contingent consideration in excess of acquisition-date fair value increased $11,899 when compared to the same period last year. This increase is driven from high payments due to high royalty bearing revenues and a shift in the classification of these payments from financing activities to operating activities. For a period of time in 2016, the cumulative life-to-date payments had not yet reached the original fair value of the related liabilities established as part of the purchase price allocation of the Éclat acquisition, and as such, the Company classified all such payments within financing activities. Payments less than the original fair value totaling $6,834 were classified within financing activities for the nine months ended September 30, 2016, compared to the same period in 2017 during which all such cash payments were classified as operating activities as the Company had exceeded the original fair value of the related liabilities established as part of the purchase price allocation of the Éclat acquisition.

- 37 -

Investing Activities

Cash used in investing activities of $15,167 for the nine months ended September 30, 2017 decreased $34,921 compared to the same prior year period. This decrease was primarily due to less net cash used in the purchase and redemption of marketable securities offset partially by $52,139 used to fund the ELAA. During the nine months ended September 30, 2017, we generated cash through the sales of net marketable securities (sales of marketable securities less purchases) of $37,505 compared to net purchases of marketable securities of $49,716 for the nine months ended September 30, 2016.

Financing Activities

Cash used in financing activities of $17,292 for the nine months ended September 30, 2017 increased $9,280 compared to the same prior year period. The increase was primarily attributed to our use of $16,707 in cash for share repurchases during the nine months ended September 30, 2017 that did not occur in 2016. This increase was partially offset by a decrease in cash used for earn-out payments for related party contingent consideration of $6,990. See Operating Activities for an explanation of the lower earn-out payments for related party contingent consideration.

Liquidity and Risk Management

We believe that our existing cash and marketable securities balances and cash we expect to generate from operations will be sufficient in the next twelve months to fund our operations and to meet our existing obligations during this time period. The adequacy of our cash resources depends on many assumptions, including primarily our assumptions with respect to product revenues and expenses, the timing and amount of commercial launch expenses related to Noctiva, as well as the other factors set forth in Part II, Item 1A (“Risk Factors”) of this quarterly report on form 10-Q and under the caption “Risk Factors” within Part I, Item 1A of the Company’s 2016 Annual Report on Form 10-K filed with the SEC. To continue to grow our business, we will need to commit substantial resources, especially associated with the commercial launch of Noctiva, which could result in future losses and significantly reduce our liquidity. Our assumptions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available cash and marketable securities balances which could, among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material adverse effect on our business.

In addition to the substantial resources we intend to commit to the commercial launch of Noctiva and the completion of our FT218 clinical trial, we will continue to evaluate a variety of strategic transactions as part of our strategy to acquire or in-license and develop additional products and product candidates. Acquisition opportunities that we pursue or have completed could materially affect our liquidity and capital resources and may require us to incur indebtedness, seek equity capital or both. Raising additional capital could be accomplished through one or more public or private debt or equity financings, collaborations or partnering arrangements. Any equity or equity-linked debt financing would be dilutive to our shareholders.

Share Repurchase Program

Other Matters

Litigation

- 38 -

or other proceeding that are reasonably likely to have a material adverse effect on the Company’s consolidated financial position, results of operations, cash flows or liquidity.

Material Commitments



Purchase Commitment:	Balance

2018	$	3,241
2019	3,704
2020	3,704
2021	3,704
2022	3,704
Thereafter	3,704
Total	$	21,761

Contractual Obligations

Disclosures regarding contractual obligations are included in Part II, Item 7 of the Company’s 2016 Annual Report on Form 10-K and updated in Note 7 – Long-Term Contingent Consideration Payable to the Company's condensed consolidated financial statements included in Part I, Item 1 of this Report.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Interest Rate Risk

The Company is subject to interest rate risk as a result of our portfolio of marketable securities. The primary objectives of our investment policy are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and competitive yield. Although our investments are subject to market risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or certain types of investment. Our investment policy allows us to maintain a portfolio of cash equivalents and marketable securities in a variety of instruments, including U.S. federal government and federal agency securities, European Government bonds, corporate bonds or commercial paper issued by U.S. or European corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, tax-exempt obligations of states, agencies, and municipalities in the U.S and Europe, and equities.

Foreign Exchange Risk

We have significant operations in Europe as well as in the U.S. Prior to December 31, 2016 each of the Company's non-U.S. subsidiaries and the parent entity, Flamel Technologies S.A., used the Euro as its functional currency. At December 31, 2016, in conjunction with the cross-border merger, the surviving entity in the merger and our new public holding company, Avadel Pharmaceuticals plc or the "Company," determined the U.S. dollar is our functional currency. The functional currency of certain foreign subsidiaries is the local currency. We are exposed to foreign currency exchange risk as the functional currency financial statements of foreign subsidiaries are translated to U.S. dollars. The assets and liabilities of our foreign subsidiaries having a functional currency other than the U.S. dollar are translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders’ equity. The reported results of our foreign subsidiaries will be influenced by their translation into U.S. dollars by currency movements against the U.S.

- 39 -

dollar. Our primary currency translation exposure is related to our subsidiaries that have functional currencies denominated in Euro.

Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and losses are reported in foreign exchange gain (loss) in the consolidated statements of income (loss). As of September 30, 2017, our primary exposure to transaction risk related to USD net monetary assets and liabilities held by subsidiaries with a Euro functional currency. Realized and unrealized foreign exchange losses resulting from transactional exposure were $362 and $109 for the three and nine months ended September 30, 2017.

ITEM 4. CONTROLS AND PROCEDURES.

Management of the Company, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company’s disclosure controls and procedures as of September 30, 2017, the end of the period covered by this quarterly report on Form 10-Q. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“Exchange Act”), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the company’s management, including its Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure. Based on their evaluation, as of the end of the period covered by this Form 10-Q, the Company’s Chief Executive Officer and Chief Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) were not effective because of the material weaknesses in our internal control over financial reporting as described in Item 9A in our Annual Report on Form 10-K as of December 31, 2016.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 or 15d-15 that occurred during the nine months ended September 30, 2017 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting, except for the Company’s continued implementation of action plans to improve the effectiveness of our internal control over financial reporting and disclosure controls and procedures. While we have made progress in all areas of our remediation plan relating to the material weaknesses described in our Form 10-K as of December 31, 2016, we specifically focused on strengthening the design and documentation of controls around our significant non-routine and complex transactions and reserves for rebates and expired products to ensure these controls are operating with an appropriate level of precision. Our Audit Committee contributes to establishing the appropriate tone at the top by emphasizing to senior leadership the importance of a sound internal control environment and also by approving our remediation plan and the subsequent monitoring of our progress.

- 40 -

PART II – OTHER INFORMATION


ITEM 1.	LEGAL PROCEEDINGS.

The information contained in Note 15 – Commitments and Contingencies to the Company's condensed consolidated financial statements included in Part I, Item 1 of this Report is incorporated by reference herein.

ITEM 1A. RISK FACTORS.

Risks related to our exclusive license agreement for Noctiva.

Consumer purchases of Noctiva are subject risks related to reimbursement from government agencies and other third parties.

We anticipate that a substantial majority of our Noctiva sales will be reimbursed by third-party payors such as the Medicare Part D program in the U.S. and private health insurance companies. The commercial success of Noctiva will therefore depend substantially on the availability and levels of reimbursements by these payors. Government authorities and private health insurance companies decide which drugs they will cover and establish payment levels, and we cannot guaranty the availability or levels of any such reimbursements for Noctiva. If reimbursement for Noctiva is unavailable or limited by governmental or private insurance programs, our Noctiva business and our results of operations will suffer a material adverse effect.

Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for Noctiva.

In recent years, government health programs such as Medicare and other third-party payors in the United States have increased their efforts to:


•	limit the price of covered drugs, including by challenging the prices charged by manufacturers, or by seeking other cost saving measures such as mandatory discounts or rebates, stricter requirements for initial reimbursement approvals and other similar measures;


•	limit the use of covered drugs, including by shifting additional cost burden to patients, typically by requiring a co-payment or co-insurance percentage that increases significantly when the medicine is not covered or is not preferred; and


•	limit the use of covered drugs by mandating treatment protocols that require additional healthcare administrative actions (in the form of a prior authorization for reimbursement) and or step edit therapy (requiring a patient to fail another therapy before getting access to the desired therapy).

Governmental agencies in the United States have enacted or adopted, are considering, and may in the future enact and adopt, various legislative and regulatory proposals to change the healthcare system, often with a particular focus on the pharmaceutical industry; and any changes resulting from such proposals may affect our ability to sell Noctiva profitably.

Any significant changes in the healthcare system in the United States would likely have a substantial impact on the manner in which we conduct our Noctiva business and could have a material adverse effect on our commercialization efforts for Noctiva.

We may have overestimated the market opportunity for Noctiva or we may not effectively exploit such market opportunity.

Our internal analyses may overstate the market opportunity in the United States for the drug desmopressin acetate, which we have licensed from Serenity Pharmaceuticals, LLC (“Serenity”) and which we intend to market under the brand name “Noctiva”. If one or more of the assumptions underlying our internal analyses are incorrect, the benefits we anticipate from our exclusive license agreement with Serenity (the “Exclusive License Agreement”) for Noctiva may not be realized or may be smaller than expected. We may also fail to effectively exploit the market opportunity for Noctiva, and such failure could have a material adverse effect on our business, financial condition and operating results.

Significant safety or drug interaction problems could arise with respect to Noctiva.

Data supporting the marketing approvals and forming the basis for the safety warnings in the product labels were derived from controlled clinical trials of limited duration in limited patient populations with Noctiva and from existing scientific knowledge and previous clinical assessments of the active pharmaceutical ingredient (Desmopressin Acetate). As Noctiva is used over longer periods of time and by more patients, some of whom may have underlying health problems or may be taking other medicines, new issues relating to safety, tolerability, resistance or drug-interaction could arise, which may require us to provide additional warnings or contraindications on product labels, or otherwise narrow Noctiva’s approved indications. Further, additional

- 41 -

information from ongoing research or clinical trials of Noctiva may raise doubts or concerns about its efficacy. If serious safety, tolerability, resistance, drug-interaction, efficacy, or any other such concerns or issues arise with respect to Noctiva, sales of Noctiva could be impaired, limited or abandoned.

We may not successfully increase awareness of nocturia and or the potential benefits of Noctiva.

Our ability to establish effective marketing and advertising campaigns for Noctiva will be key to our success in commercializing the drug. If we are unable to increase awareness of nocturia (i.e., adult night-time non-incontinent urination, which Noctiva is intended to reduce), the establishment of nocturnal polyuria as the critical etiology that must be treated despite any other co-morbidities and the potential benefits of Noctiva, our efforts to build a substantial customer base for the drug may not be successful. In addition, our overall marketing activities or pricing strategies may not be successful in promoting or selling Noctiva. If our marketing and advertising programs are not adequate to support future growth of Noctiva sales, our expected results may experience a material adverse effect.

We depend on a third-party supplier to manufacture Noctiva and any failure of such supplier to deliver sufficient quantities of Noctiva would have a material adverse effect on our business.

We will depend on a single contract manufacturing organization, Renaissance Lakewood, LLC, for the manufacturing and supply of Noctiva. If the supplies of Noctiva are interrupted for any reason, our manufacturing and marketing of Noctiva could be delayed. These delays could be extensive and expensive, especially in situations where a substitute is not readily available, or where additional regulatory approval is required. Failure to obtain adequate supplies in a timely manner could have a material adverse effect on our business, financial condition and results of operations.

We may be unable to adequately protect or enforce the intellectual property rights relating to Noctiva.

We may fail to adequately protect and enforce the intellectual property rights relating to Noctiva, and such failure could have a material adverse effect on our success. The patent positions of biopharmaceutical products or formulas can be highly uncertain and can involve complex legal and factual questions. The patent rights licensed to us under the Exclusive License Agreement may not be upheld in a court of law if challenged or may not provide a competitive advantage for Noctiva, and may be infringed upon or circumvented by our competitors. Because of the large number of patent filings in the biopharmaceuticals field, our competitors may have filed applications, may have been issued patents, or may obtain additional patents and proprietary rights relating to substances or processes competitive with or similar to Noctiva. We cannot be certain that U.S. or Canadian patents do not exist or will not be issued that would harm our ability to successfully commercialize Noctiva in such markets.

Our costs to commercialize Noctiva could exceed our estimates or such costs may not provide the intended results.

Our past and future internal budgets, plans and projections may underestimate the costs we will incur to develop and commercialize Noctiva, including transaction and integration costs and the costs of other financial, business and strategic initiatives related to the Exclusive License Agreement. Even if we adequately control such costs, our expenditures in developing and commercializing Noctiva may not yield the desired results. Further, we may incur higher than expected operating costs, and we may encounter general economic and business conditions that adversely affect us relating to the Exclusive License Agreement.

The development and commercialization of Noctiva will likely require significant management attention, which could disrupt our business and adversely affect our financial results.

We anticipate that our management will devote substantial time and attention to develop and commercialize Noctiva. By diverting management’s attention away from our other products, our ongoing operations could suffer, which could have a material adverse effect on our business, financial condition, results of operations or prospects.

Other than the foregoing, there were no material changes to the risk factors previously disclosed in the Company’s 2016 Annual Report on Form 10-K under Item 1A. Risk Factors.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS.

(In thousands, except per share data)

The following table summarizes the repurchase activity of our ordinary shares during the three and nine months ended September 30, 2017. The repurchase activity presented below includes both market repurchases of shares and deemed repurchases in connection with the vesting of restricted share units under employee benefit plans to satisfy minimum statutory tax withholding obligations.

- 42 -

the open market, in block transactions on or off the exchange, in privately negotiated transactions, or through other means as determined by the Board of Directors and in accordance with the regulations of the Securities and Exchange Commission. The timing and amount of repurchases, if any, will depend on a variety of factors, including the price of our shares, cash resources, alternative investment opportunities, corporate and regulatory requirements and market conditions. This share repurchase program may be modified, suspended or discontinued at any time without prior notice. We may also from time to time establish a trading plan under Rule 10b5-1 of the Securities and Exchange Act of 1934 to facilitate purchases of our shares under this program. As of September 30, 2017, the Company had repurchased approximately 1,673 ordinary shares for $17,506 detailed below:



	Total Number of Shares Purchased	Average Price Paid Per Share		Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number (or Approximate Dollar Value) of Shares That May Yet Be Purchased Under Plans or Programs

April 2017	—	$	—	—	$	25,000
May 2017	316	9.94		316	21,864
June 2017	1,035	10.82		1,035	10,662
July 2017	—	—		—	10,662
August 2017	—	—		—	10,662
September 2017	322	9.84		322	7,494
Total	1,673

ITEM 3. DEFAULTS UPON SENIOR SECURITIES.

None.

ITEM 4. MINE SAFETY DISCLOSURES.

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

- 43 -

ITEM 6. EXHIBITS.



Exhibit No.		Description

10.1*⁺		Employment Agreement by and between Avadel Management Corporation and Michael S. Anderson dated August 15, 2017.
10.2*⁺		Employment Agreement by and between Avadel Management Corporation and Gregory J. Divis dated September 5, 2017.
10.3*⁺		Employment Agreement by and between Avadel Management Corporation and Sandra Hatten dated August 15, 2017.
10.4*⁺		Employment Agreement by and between Avadel Management Corporation and Michael F. Kanan dated September 5, 2017.
10.5*⁺		Employment Agreement by and between Avadel Management Corporation and Phillandas T. Thompson dated August 15, 2017.
10.6*‡		Exclusive Right of Negotiation Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of August 11, 2017.
10.7*‡		Exclusive License and Assignments Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of September 1, 2017.
10.8A*‡		Manufacturing Agreement by and between Renaissance Lakewood, LLC (formerly DPT Lakewood, LLC) and Serenity Pharmaceuticals, LLC dated as of July 14, 2014.
10.8B*		Renaissance Agreements Assignment and Assumption Agreement by and between Avadel Specialty Pharmaceuticals, LLC and Serenity Pharmaceuticals, LLC dated as of September 1, 2017.
10.9*		Master Manufacturing Services Agreement by and between Patheon UK Limited and Éclat Pharmaceuticals L.L.C. dated as of November 8, 2012.
31.1*		Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act.
31.2*		Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) promulgated under the Exchange Act.
32.1**		Certification of the Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**		Certification of the Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*		XBRL Instance Document
101.SCH*		XBRL Taxonomy Extension Schema Document
101.CAL*		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB*		XBRL Taxonomy Extension Label Linkbase Document
101.PRE*		XBRL Taxonomy Extension Presentation Linkbase Document

______________________

* Filed herewith.

** Furnished herewith.

+ Indicates management contract or compensatory plan or arrangement.

‡ Confidential treatment has been requested for the redacted portions of this agreement. A complete copy of the agreement, including the redacted portions, has been filed separately with the Securities and Exchange Commission.

- 44 -

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on our behalf by the undersigned thereunto duly authorized.



	AVADEL PHARMACEUTICALS PLC
	(Registrant)

Date: November 9, 2017	By:	/s/ Michael F. Kanan
		Michael F. Kanan
		Senior Vice President and Chief Financial Officer
		(Duly Authorized Officer and Principal Financial Officer)

- 45 -